








The copyright of this thesis rests with the University of Cape Town. No 
quotation from it or information derived from it is to be published 
without full acknowledgement of the source. The thesis is to be used 













FIERDOZ OMAR OMRFIE001 MMED (CHEMICAL PATHOLOGY)  
Fierdoz Omar OMRFIE001 
Master of Medicine (Chemical Pathology) 
Faculty of Health Sciences  
University of Cape Town 
 
 






INVESTIGATION OF HIGH MOLECULAR WEIGHT 




Submitted to the  
 
UNIVERSITY OF CAPE TOWN 
 
 
In partial fulfilment of the requirements for the degree 
 
 















FIERDOZ OMAR OMRFIE001 MMED (CHEMICAL PATHOLOGY)  
SUPERVISOR 
Professor Tahir S Pillay 
MBChB, PhD, FRCPath(UK) & FCPath(SA) 
Head of Division, Chemical Pathology 
Department of Clinical Laboratory Sciences, Faculty of Health Sciences 




Dr Judy King  
BSc(Hon), MSc, PhD 
Division of Chemical Pathology 
Department of Clinical Laboratory Sciences, Faculty of Health Sciences 






















FIERDOZ OMAR OMRFIE001 MMED (CHEMICAL PATHOLOGY) 
DECLARATION 
I, Fierdoz Omar, hereby declare that the work on which this dissertation is based is 
my original work (except where acknowledgements indicate otherwise) and that 
neither the whole work nor any part of it has been, is being, or is to be submitted 
for another degree in this or any other university.  
This work has not been published prior to registration for the abovementioned 
degree. 
I empower the university to reproduce for the purpose of research either the whole 
or any portion of the contents in any manner whatsoever. 
Signature: …………………………. 
Date: ……22 February 2010….…. 
Revisions have been made to the original document. This declaration still holds. 
Signature: …………………………. 











Signature RemovedSigned by Candidate
Signed by Candidate Signature Removed
 
iv 
FIERDOZ OMAR OMRFIE001 MMED (CHEMICAL PATHOLOGY)  
ACKNOWLEDGEMENTS 
The following are gratefully acknowledged: 
My family for making it possible for me to pursue this degree; Prof Tahir Pillay and 
Dr Judy King for their guidance and instruction; Prof Naomi Levitt and Dr Joel 
Dave for providing patient samples and data; Sacha West for helping with sample 
collection; Felicity Leisegang and Wan Iryani Wan Ismail for their instruction on 
Western blotting; Jenny Kannemeyer for her instruction on ELISAs, Dr Andrew 
Boulle for help with statistical analysis and the National Health Laboratory Service 













FIERDOZ OMAR OMRFIE001 MMED (CHEMICAL PATHOLOGY)  
 
Table of Contents 
DECLARATION .................................................................................... iii 
ACKNOWLEDGEMENTS .................................................................... iv 
LIST OF ABBREVIATIONS .................................................................. 2 
A. RESEARCH PROTOCOL FOR MMED DISSERTATION ....................... 4 
A.1. TITLE ....................................................................................................... 5 
A.2. SHORT DESCRIPTION OF THE PROJECT ........................................................ 5 
A.3. AIMS AND OBJECTIVES.............................................................................. 5 
A.3.1. Broad aims....................................................................................... 5 
A.3.2. Objectives ........................................................................................ 6 
A.4. BACKGROUND .......................................................................................... 6 
A.5. RESEARCH PLAN ....................................................................................... 9 
A.6. DETAILED METHODOLOGY...................................................................... 10 
A.6.1. Study population............................................................................. 11 
A.6.2. Laboratory assays .......................................................................... 12 
A.6.2.1. Adiponectin assay................................................................... 12 
A.6.2.2. Immunoblotting of adiponectin species................................... 13 
A.7. ENVISAGED OUTPUTS/OUTCOMES ............................................................ 13 
A.8. IMPACT................................................................................................... 14 
A.9. INSTITUTIONAL APPROVAL...................................................................... 14 
A.10. BUDGET.............................................................................................. 15 
A.11. FUNDING ............................................................................................ 15 
A.12. REFERENCES ....................................................................................... 15 
B. LITERATURE REVIEW............................................................................ 18 
B.1. OBJECTIVES ............................................................................................ 18 
B.2. SEARCH STRATEGY AND QUALITY CRITERIA ............................................. 18 
B.3. SUMMARY OF LITERATURE ...................................................................... 18 
B.3.1. Introduction ................................................................................... 18 
B.3.2. HIV-associated lipodystrophy......................................................... 20 
B.3.2.1. Risk factors for the development of lipodystrophy .................. 20 













FIERDOZ OMAR OMRFIE001 MMED (CHEMICAL PATHOLOGY)  
Role of protease inhibitors in the pathogenesis of lipodystrophy............. 21 
Role of NRTIs/NNRTIs in the pathogenesis of lipodystrophy ................ 22 
B.3.3. Adiponectin .................................................................................... 23 
B.3.3.1. Regulation of adiponectin synthesis and secretion................... 25 
B.3.3.2. Metabolic and anti-inflammatory effects of adiponectin.......... 27 
Adiponectin receptors ............................................................................ 27 
Insulin sensitising actions of adiponectin via AMP kinase...................... 27 
Insulin sensitising actions via activation of PPARα ................................ 28 
Anti-atherosclerotic action of adiponectin .............................................. 28 
B.3.3.3. Adiponectin in the clinical scenario ........................................ 29 
B.3.3.4. HMW adiponectin .................................................................. 29 
B.3.3.5. Measurement of adiponectin isoforms..................................... 30 
B.3.4. Adiponectin in HIV......................................................................... 31 
B.3.5. HIV-associated lipodystrophy and the risk for CAD ....................... 33 
B.3.6. Conclusion and needs for future research....................................... 33 
B.4. REFERENCES........................................................................................... 34 
C. MANUSCRIPT ............................................................................................ 46 
C.1. TITLE.................................................................................................... 46 
C.2. ABSTRACT .......................................................................................... 48 
C.3. LIST OF ABBREVIATIONS................................................................. 49 
C.4. BACKGROUND ........................................................................................ 49 
C.5. METHODS ............................................................................................... 51 
Statistical analysis.................................................................................. 52 
C.6. RESULTS................................................................................................. 52 
Patient characteristics............................................................................. 52 
Adiponectin levels in serum ................................................................... 53 
Traditional markers of insulin resistance and dyslipidaemia ................... 54 
Correlates of adiponectin........................................................................ 55 
Multivariate analysis .............................................................................. 56 
Power analysis for major variables ......................................................... 56 
C.7. DISCUSSION ............................................................................................ 57 
C.8. CONCLUSION .......................................................................................... 60 













FIERDOZ OMAR OMRFIE001 MMED (CHEMICAL PATHOLOGY)  
C.10. TABLES AND FIGURES.......................................................................... 65 
C.11. SUPPLEMENTAL DATA ................................................................. 71 
Anthropometry....................................................................................... 71 
PI patients .............................................................................................. 71 
Medium molecular weight adiponectin................................................... 71 
Lipodystrophy findings .......................................................................... 72 
Correlations ........................................................................................... 76 
Multivariate analyses ............................................................................. 83 
D. SUPPORTING DOCUMENTS................................................................... 92 
D.1. ETHICS APPROVAL .................................................................................. 92 
D.2. COVER LETTER AND ETHICS APPROVAL FOR AMENDMENT OF RESEARCH 
PROTOCOL .......................................................................................................... 93 
D.3. PATIENT CONSENT FORM (FROM DR JOEL DAVE’S STUDY) ......................... 95 
D.4. PATIENT INFORMATION SHEET (FROM DR JOEL DAVE’S STUDY) ................. 96 
D.5. PROCEDURE FOR MULTIMERIC ADIPONECTIN ANALYSIS (FROM PACKAGE 
INSERT) .............................................................................................................. 98 
D.6. OUTCOMES ACHIEVED........................................................................... 103 
D.7. CLINICAL CHEMISTRY GUIDELINES FOR SUBMISSION OF MANUSCRIPT...... 108 
D.8. UNIVERSITY OF CAPE TOWN DISSERTATION GUIDELINES ........................ 124 
  
 
Listing of Figures & Tables (Manuscript)  
Figures 
Literature Review and Supplemental Data Figures 
Figure 1: Replication of HIV and inhibition by antiretroviral drugs. Pomerantz et al. 
Twenty years of therapy for HIV-1 infection. Nat Med 2003; 9(7):867-873........... 19 
Figure 2: Multimeric forms of adiponectin; LMW, MMW and HMW are the low, 
medium and high molecular weight forms of adiponectin, respectively. Kadowaki et 
al. Adiponectin and adiponectin receptors. Endo Rev  2005; 26(3):439–451. ......... 25 
Figure 3: Diagram showing regulation of adiponectin at the gene level. Many factors 













FIERDOZ OMAR OMRFIE001 MMED (CHEMICAL PATHOLOGY)  
Transcriptional and post-translational regulation of adiponectin. Biochem J 2010; 
425: 41–52. ........................................................................................................... 26 
Supplemental Data Figure 6: The  relationship between HMW: total adiponectin  
ratios in serum and BMI. rs is the Spearman correlation coefficient; p<0.05 deemed 
statistically significant. .......................................................................................... 78 
Supplemental Data Figure 7: Relationship between HMW:  total adiponectin ratios 
in serum and WHR. rs is the Spearman correlation coefficient; p<0.05 deemed 
statistically significant. .......................................................................................... 79 
Supplemental Data Figure 8: Relationship between HMW: total adiponectin  ratio 
and waist measurement. rs is the Spearman correlation coefficient; p<0.05 deemed 
statistically significant. .......................................................................................... 79 
Supplemental Data Figure 9: Relationship between HMW: total adiponectin and 
fasting insulin concentration in serum. rs is the Spearman correlation coefficient; 
p<0.05 deemed  statistically significant. ................................................................ 80 
Supplemental Data Figure 10: Relationship between HMW: total adiponectin ratio 
and HOMA-IR. rs is the Spearman correlation coefficient; p<0.05 deemed 
statistically significant. .......................................................................................... 80 
Supplemental Data Figure 11: Relationship between HMW: total adiponectin ratio 
and QUICKI. rs is the Spearman correlation coefficient; p<0.05 deemed statistically 
significant.............................................................................................................. 81 
Supplemental Data Figure 12: Relationship between HMW: total adiponectin ratio 
and serum triglyceride concentration. rs is the Spearman correlation coefficient; 
p<0.05 deemed statistically significant. ................................................................. 81 
Supplemental Data Figure 13: Relationship between CD 4 count and HMW: total 
adiponectin ratio in    serum. rs is the Spearman correlation coefficient; p<0.05 
deemed statistically significant. ............................................................................. 82 
Manuscript Figures 
Manuscript Figure 1: Box and whisker plots showing distribution of (a)total 
adiponectin, (b)HMW adiponectin, (c)HMW: total adiponectin ratio and (d)LMW: 













FIERDOZ OMAR OMRFIE001 MMED (CHEMICAL PATHOLOGY)  
LMW, low molecular weight; KW, Kruskall-Wallis; p <0.05 considered significant.
.............................................................................................................................. 69 
Manuscript Figure 2: Distribution of HMW: total adiponectin ratio in patients with 
(a) HOMA-IR ≤ or > 1.95 and (b) BMI < 25 or  ≥ 25. HMW, high molecular weight; 
KW, Kruskall-Wallis; p<0.05 considered significant. ............................................ 70 
 
Tables 
Table 1: Antiretroviral drug combinations in the two treatment groups. PI, protease 
inhibitor; non-PI, non- protease inhibitor; LPV/r, liponavir/ritonavir; ddI, 
didanosine; AZT, zidovudine; 3TC, lamivudine; EFV, efavirenz. .......................... 65 
Table 2: Duration of therapy (months) and CD 4 counts (x 106 per litre) among the 
groups. PI, protease inhibitor group; non-PI, non- protease inhibitor group; d4T, 
stavudine; AZT, zidovudine; IQR, inter-quartile range; *= p-value indicating 
significant difference between PIs and non-PIs; **= p-value indicating significant 
different between non-PIs and TNs; *** = p-value indicating significant difference 
between PIs and TN............................................................................................... 66 
Table 3: Median and inter-quartile ranges for the different variables in the three 
groups. P <0.05 demonstrates a significant difference for the variable among the 
groups. PI, protease inhibitor group; nonPI, non- protease inhibitor group; WHR, 
waist: hip ratio; HMW, high molecular weight; MMW, medium molecular weight; 
LMW, low molecular weight; HDL, high density lipoprotein, LDL, low density 
lipoprotein; KW, Kruskall-Wallis; IQR, inter-quartile range. ................................. 67 
Table 4: Spearman correlation coefficient (rs) for significant correlations between 
adiponectin fractions and variables listed (p < 0.05). BMI, body mass index; HMW, 
MMW and LMW, high, medium and low molecular weight, respectively; ns, not 
significant.............................................................................................................. 68 
 
Supplemental Data Table 1:  MMW (in ug/ml), its ratio to total adiponectin  and the 
lipodystrophy scores: median (IQR). P<0.05 deemed a significant difference among 













FIERDOZ OMAR OMRFIE001 MMED (CHEMICAL PATHOLOGY)  
Supplemental Data Table 2 : Distribution of lipodystrophy in HIV-infected patients 
in the different treatment groups. ........................................................................... 74 
Supplemental Data Table 3: Mann-Whitney U derived p-values for differences 
between the various groups. p <0.05 deemed significant difference. ...................... 75 
Supplemental Data Table 4: Spearman correlation coefficients (rs) showing the 
relationships between the different variables. Numbers in bold are significant with 
p<0.05. .................................................................................................................. 76 
Supplemental Data Table 5: : Multivariate analysis adjusting for BMI, showing the 
correlations between waist measurement and total and HMW (high molecular 
weight) adiponectin and ratio, respectively.* = significant p<0.05. ........................ 83 
Supplemental Data Table 6: Multivariate analyses adjusting for BMI showing the 
correlations between fasting insulin concentration and total and HMW (high 
molecular weight) adiponectin and ratio, respectively. *= significant p<0.05......... 84 
Supplemental Data Table 7: Multivariate analysis, adjusting for BMI, showing the 
corrrelations between HOMA-IR and total and HMW (high molecular weight) 
adiponectin and ratio, respectively.  *= significant p<0.05. .................................... 85 
Supplemental Data Table 8: Multivariate analysis, adjusting for BMI, showing the 
correlations between QUICKI and total and HMW (high molecular weight) 
adiponectin and ratio, respectively. *= significant p<0.05...................................... 86 
Supplemental Data Table 9: Multivariate analysis, adjusting for duration of HAART, 
showing the correlation between CD 4 count and total, HMW (high molecular 
weight) adiponectin and ratio, respectively. *= significant p<0.05. ........................ 87 
Supplemental Data Table 10: Multivariate analysis, adjusting for duration of 
HAART, showing the relationship between waist measurement and CD 4 count. 
*=significant p<0.05.............................................................................................. 88 
Supplemental Data Table 11: Multivariate analysis adjusting for BMI, showing the 
correlations between fasting insulin concentration and MMW (medium molecular 
weight) adiponectin and the LMW (low molecular weight): total adiponectin ratio, 
respectively. *= significant p<0.05. ....................................................................... 89 
Supplemental Data Table 12: Multivariate analysis adjusting for BMI, showing the 













FIERDOZ OMAR OMRFIE001 MMED (CHEMICAL PATHOLOGY)  
and the LMW (low molecular weight): total adiponectin ratio, respectively. *= 
significant p<0.05.................................................................................................. 90 
Supplemental Data Table 13: Multivariate analysis adjusting for BMI, showing the 
correlations between QUICKI and MMW (medium molecular weight) adiponectin 
and the LMW (low molecular weight): total adiponectin ratio, respectively. *= 













FIERDOZ OMAR OMRFIE001 MMED (CHEMICAL PATHOLOGY)  
 Page 2 of 135 
LIST OF ABBREVIATIONS 
AdipoR1 Adiponectin receptor 1 
AdipoR2 Adiponectin receptor 2 
ADP  Adenosine diphosphate 
AIDS  Acquired immunodeficiency syndrome 
AMP  Adenosine monophosphate 
AMPK  AMP-dependent protein kinase 
Apo  Apolipoprotein  
ARV  Antiretroviral 
ATP  Adenosine triphosphate 
AZT  Zidovudine 
BMI  Body mass index 
CAD  Coronary artery disease 
CD4  Cluster of differentiation 4 
CD36  Cluster of differentiation 36 
C/EBP  CCAAT-enhancer-binding protein 
CRABP-1 Cytoplasmic retinoic-acid binding protein-1 
CRP  C-reactive protein 
CTRP  c1q-tumour necrosis factor related protein 
DNA  Deoxyribonucleic acid 
ELISA  Enzyme-linked immunosorbent assay 
FOXO1 Forkhead box O1 
FPLC  Fast protein liquid chromatography 
GLUT4 Glucose transporter 4 
HAART Highly active antiretroviral therapy 
HD  High density lipoprotein 
HIV  Human immunodeficiency virus 
HMW  High molecular weight 
HOMA-IR Homeostasis model assessment–insulin resistance 
HPLC  High performance liquid chromatography 













FIERDOZ OMAR OMRFIE001 MMED (CHEMICAL PATHOLOGY)  
 Page 3 of 135 
IκB  Inhibitor of Nuclear Factor-κB 
IL  Interleukin 
LDL  Low density lipoprotein 
LMW  Low molecular weight 
LRP  Low density lipoprotein receptor-related protein 
Lp(a)  Lipoprotein (a) 
MMW  Medium molecular weight 
mRNA  Messenger ribonucleic acid 
mtDNA Mitochondrial deoxyribonucleic acid 
NRTI  Nucleotide or nucleoside reverse transcriptase inhibitor 
NNRTI Non-nucleotide reverse transcriptase inhibitor 
PGC1  Peroxisome proliferator activated receptor coactivator 1  
PI  Protease inhibitor 
PPAR  Peroxisome proliferator activated receptor 
PVDF  Polyvinylidene fluoride 
QUICKI Qualitative insulin-sensitivity check index 
RIA  Radioimmunoassay 
RNA  Ribonucleic acid 
ROS  Reactive oxygen species 
RXR  Retinoid X receptor 
SDS  Sodium dodecyl sulphate 
SIRT  Sirtuin 
SREBP-1c Steroid response element binding protein -1c 
TNF  Tumour necrosis factor 
VCAM Vascular cellular adhesion molecule 














FIERDOZ OMAR OMRFIE001 MMED (CHEMICAL PATHOLOGY)  
 Page 4 of 135 
A. RESEARCH PROTOCOL FOR MMED DISSERTATION 
APPLICANT: 
Dr Fierdoz Omar: Registrar 
   National Health Laboratory Service 
   Division of Chemical Pathology 
University of Cape Town and Groote Schuur Hospital 
   MP 0499366 
   fierdoz.omar@uct.ac.za 
   tel: 021 404 4135 
  
Degree registered: MMed (Chemical Pathology) 
Year initially registered: 2005 
Current year of registration: II 
SUPERVISOR: 
Prof Tahir Pillay: Head, Division of Chemical Pathology 
   Groote Schuur and Red Cross Childrens Hospitals 
   University of Cape Town 
   MP 027590 
   profts.pillay@uct.ac.za    




Dr Judy King:  Principal Medical Scientist 
Division of Chemical Pathology 
National Health Laboratory Service  
Groote Schuur Hospital 
KB 0000299 
judy.king@uct.ac.za  
                                                
1
 Dr King has subsequently become co-supervisor for this project, while Professor N Levitt and Dr J Dave 













FIERDOZ OMAR OMRFIE001 MMED (CHEMICAL PATHOLOGY)  
 Page 5 of 135 




Role of high molecular weight (HMW) multimeric adiponectin in the development of 
HIV-lipodystrophy syndrome following anti-retroviral therapy 
 
A.2. SHORT DESCRIPTION OF THE PROJECT 
 
This project aims to investigate the role of multimeric (high molecular weight) 
adiponectin in the development of metabolic disease resulting from anti-retroviral 
therapy.  Specifically, the aim is to quantify the circulating levels of both total and high 
molecular weight (HMW) adiponectin and to establish whether a link exists between 
HMW adiponectin levels and susceptibility to HIV-induced lipodystrophy. Although total 
adiponectin levels have been shown to be significantly reduced in patients with HIV-
induced lipodystrophy, there is no information on whether HMW adiponectin, which 
appears to be the most biologically active form of adiponectin, is altered in HAART-
induced lipodystrophy, and whether patients with low levels of the HMW form are more 
susceptible to lipodystrophy.   
 
A.3. AIMS AND OBJECTIVES 
 
A.3.1. Broad aims 
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A.3.2. Objectives  
• Quantify total and HMW adiponectin levels in patients with HIV-lipodystrophy 
syndrome2; 
• Determine whether susceptibility to HIV- lipodystrophy is related to low 
circulating levels of the HMW multimeric form. 
 
If indeed HMW adiponectin levels are implicated, then in the future there may be a 
possibility that HMW adiponectin infusions could be used to treat HAART-induced 
lipodystrophy and the associated metabolic disturbances. Recombinant adiponectin is 




Infection with HIV and consequent AIDS is a major public health problem in South 
Africa and the rest of the world. The prognosis of patients has been improved 
dramatically by the use of combination therapy based on HIV protease inhibitors and 
reverse transcriptase inhibitors.   The use of highly active antiretroviral therapy 
(HAART) to suppress viral replication and restore immunity has improved prognosis of 
patients to such a degree that long-term complications are becoming more prevalent.  One 
major complication is the HIV-lipodystrophy syndrome, which appears to have a 
metabolic and biochemical component. Initially these were observed with protease 
inhibitors, but they have also been seen with both non-nucleoside analogues and one 
nucleoside analogue (stavudine). The components of the syndrome include 
lipodystrophy, raised triglycerides and cholesterol, and insulin resistance, which may be 
associated with hyperglycaemia [1, 2]. Lipodystrophy refers to either loss of 
subcutaneous fat (peripheral fat wasting, termed lipoatrophy), fat tissue deposition 
subcutaneously or in visceral stores (fat accumulation, termed lipohypertrophy), or a 
                                                
2
 Due to low roll-out of anti-retroviral therapy at our clinics and therefore the low prevalence of 
lipodystrophy, we later amended this objective to quantifying Multimeric adiponectin levels in patients on 
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combination of the two. However, there are as yet no standardised criteria for diagnosing 
lipodystrophy clinically and metabolically. Diagnosis in a previous study was based on 
concordance between the opinions of subject and clinician[3]. 
 
The consequences of this syndrome are that patients on therapy are at increased risk for 
developing cardiovascular diseases as a result of HAART, and changes in body fat, 
manifested by the loss of facial and limb adipose tissue and central obesity as a result of 
lipodystrophy, may prompt patients to reject treatment.  The body fat changes occur in 
about 40% of patients on HAART[2].  Lipid levels are affected particularly by Ritonavir, 
which increases LDL cholesterol, triglycerides and Lp(a).  With lipodystrophy comes an 
increased risk of insulin resistance and diabetes[2].  
 
The mechanisms underlying the development of lipodystrophy are poorly understood. It 
has been suggested that these metabolic abnormalities arise from hormonal perturbations, 
and disturbances in the regulation and secretion of adipokines such as adiponectin have 
been implicated.   
 
Adiponectin is a 244-amino acid peptide hormone secreted by adipocytes [4], and 
circulating levels of adiponectin correlate with the amount of adipose tissue [5, 6]. 
Adiponectin circulates in the blood in a wide range of multimer complexes, existing in 3 
major oligomeric forms viz. a low molecular weight trimer, a mid-molecular weight 
hexamer and a high molecular weight (HMW) multimeric form of 12 to 18 peptide 
molecules. Adiponectin binds to two seven-transmembrane domain-type receptors 
(AdipoR1 and -R2) [7], AdipoR1 is found mainly in muscle, whereas AdipoR2 
predominates in the liver.  
 
Adiponectin has several different physiological actions, such as protective activities 
against atherosclerosis, improvement of insulin sensitivity, and prevention of hepatic 
fibrosis. It enhances fatty acid oxidation in muscle [8] and enhances insulin action in the 
liver [9]. In mice with insulin resistance associated with lipoatrophy or obesity, 
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resistance and glucose intolerance, and vascular disease develop in adiponectin knockout 
mice [11]. Furthermore, type 2 diabetics have low adiponectin levels, especially in 
association with coronary artery disease [12], while improved insulin sensitivity in these 
patients, when treated with thiazolidinediones, is associated with increased expression of 
adiponectin [13]. Thiazolidinediones have also been shown to increase adiponectin 
expression in obese mice [14]. 
 
Recent studies indicate that the HMW multimeric form of adiponectin, rather than total 
adiponectin, has a significant predictive role in disease status [15, 16]. The individual 
structures of adiponectin multimers in human plasma have been elucidated, which has led 
to the discovery of an albumin-binding trimer, in addition to the already documented 
trimeric, hexameric and HMW forms [17]. Part of the multimeric form is selectively 
digested by certain proteases and it is now possible to introduce a pre-treatment step to 
selectively digest the low and mid- molecular weight forms, allowing measurement of the 
HMW form. 
 
It is also possible to separate all the individual multimeric species using other techniques 
such as velocity sedimentation in sucrose gradients, HPLC, FPLC and immunoblotting, 
but these are not suitable for high throughput measurement involving many samples [17]. 
We do, however, plan to validate the results obtained, using immunoblotting. 
 
A recent study has shown that plasma adiponectin levels have relatively low 
biovariability and that adiponectin can be sampled fasted or non-fasted due to only minor 
diurnal and post-prandial changes[18]. 
Plasma adiponectin levels vary minimally over 12 – 15 months, suggesting that a single 
adiponectin measurement may be adequate for risk assessment[18, 19]. Adiponectin has 
also been shown to be stable for 33 months (or 3 freeze-thaw cycles) when stored at -
30°C[19].   
 
Total adiponectin levels have been shown to be decreased in patients with HIV-
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levels in circulation has been shown to be a more accurate reflection of disease status. 
The relative levels in HIV-associated lipodystrophy are not known. This project aims to 
address this.  
 
A.5. RESEARCH PLAN 
 
This project will run over 12 to 18 months. The first 6 to 8 months will be dedicated to 
obtaining subject and control groups from the ARV clinics at Groote Schuur and Jooste 
Hospitals. Blood samples will be drawn from these patients and stored. Over the next 2 to 
3 months, adiponectin analyses will be done by ELISA and Western blot3.  
All equipment required is available in the C17 Core Laboratory, as well as in the Division 
of Chemical Pathology, UCT. 
Once all data have been collected, data analysis will be done, conclusions drawn and any 
additional requirements attended to. This process should be completed within 3 to 6 
months. 
Dr Fierdoz Omar will be responsible for subject and control sample collection, as well as 
adiponectin analyses and data analysis4. This will be done in collaboration with Dr Judy 
King and under the supervision of Prof. Tahir Pillay. 
                                                
3
 Western blot analysis was subsequently not performed following work published by Liu et al. in Clinical 
Chemistry (Liu et al. Comparison of immunoassays for the selective measurement of human high-
molecular weight adipoenctin. Clin Chem, 2009. 55(3):568-72.), validating the multimeric adiponectin 
concentrations obtained by ELISA with Western blot analysis. 
4
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A.6. DETAILED METHODOLOGY 
 
The project will be reviewed by the local ethics committee and approval obtained. 
Written informed consent (see attached consent form) will be obtained from test subjects 
and controls, and baseline blood samples obtained. Subjects will be given a questionnaire 
to assess the presence of lipodystrophy and this will be confirmed by clinical examination 
(concordance between the subject’s opinion and that of the clinician, that at least 
moderate changes have occurred, will be considered as diagnostic of lipodystrophy). 






Western  Blot 
Recruitment of Subjects & Controls  
Patient Informed Consent 
Sample Collection & Storage 
 
Data Analysis 
Additional testing / 
changes as required 
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Additional data will be obtained from the patients’ routine management information and 
will include the following: demographic data, specific HAART therapy prescribed and 
biochemical tests, which may include lipid studies, glucose and insulin levels. 
A.6.1. Study population 
 
The study population will consist of South African blacks and will be divided into 4 
groups5: 
One test group consisting of: 
50 known HIV positive adult patients on antiretroviral treatment, with lipodystrophy 
And four control groups:  
• HIV positive patients on antiretroviral therapy but without lipodystrophy 
• HIV positive patients with lipodystrophy but not on antiretroviral therapy  
• HIV positive patients without lipodystrophy and not on antiretroviral therapy 
• Non-diabetic healthy controls 
 
The subjects and controls will be matched for age and gender. Persons with known 
diabetes mellitus or obesity (BMI>30) will be excluded6. 
 
A total of 30 samples from each control group will be assayed. HIV patients will be 
sourced from HIV anti-retroviral roll-out clinics at Groote Schuur and Jooste Hospitals in 
the Western Cape7. 
                                                
5
 As mentioned earlier, patients with lipodystrophy were few in number and therefore the study 
population was changed to the following: 30 HIV-infected patients in each of the following groups: (a) 
treatment-naïve; (b) patients receiving HAART without protease inhibitors; (c) patients receiving HAART 
including a protease inhibitor; as well as 30 HIV-negative subjects. We were unable to obtain age- and 
BMI-matched HIV-negative subjects, and therefore the first three groups only were used in this study. 
6
 Obese patients were subsequently included in the study. 
7
 Subject and control sample collection, patient consent, clinical data and biochemical data (excluding 
adiponectin levels) were obtained by Dr Joel Dave (Division of Endocrinology, UCT & GSH) for a larger 
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A.6.2. Laboratory assays 
A.6.2.1. Adiponectin assay  
The protocol to be followed is as follows. A blood sample will be collected in an EDTA 
tube. The plasma will first undergo pre-treatment with proteases and SDS-buffer. The 
pre-treated specimen will then be assayed by enzyme linked immunosorbant assay 
(ELISA), using the  Adiponectin (Multimeric) EIA kit marketed by ALPCO Diagnostics 
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This method allows for the quantitative and selective determination of HMW, MMW 
(mid-molecular weight), LMW (low molecular weight) and total adiponectin levels. 
This new ELISA assay for multimeric forms of adiponectin will first be validated by 
correlation with the adiponectin RIA assay which is currently being used for 
quantification of total adiponectin. 
 
A.6.2.2. Immunoblotting of adiponectin species8 
Approximately 30ul of serum will be used for immunoblotting under both native and 
denaturing conditions. Native gels will allow detection of the multimeric species prior to 
denaturation.  The sample will be treated with electrophoresis sample buffer and then 15 
ul will be loaded onto a 7.5% polyacrylamide gel (Biorad Miniprotean) and then 
subjected to electrophoresis at 150V for 1 hour. Following this, the gels will then be 
transferred to PVDF membranes at 250mA for 2 hours. The membranes will then be 
blocked with 5% Marvel and then probed with goat anti-adiponectin goat antibody (Santa 
Cruz Biotechnology). Bound antibody will be visualised using a second (rabbit) anti-goat 
antibody coupled to horse radish peroxidise, using chemiluminescence (SuperSignal, 
Pierce Chemical Company). The amount of chemiluminescence will then be quantified 
using an imager or by densitometry of X-ray films. Both facilities are available in the 
Division of Chemical Pathology at the University of Cape Town.  
 
A.7. ENVISAGED OUTPUTS/OUTCOMES 
 
It is envisaged that this study will provide more insight into the molecular basis for the 
development of lypodystrophy in HIV patients on antiretroviral treatment, and that this 
knowledge may lead to therapeutic improvement. The results from this study will be 
presented at the SA Society for Clinical Biochemistry meeting, the SEMSDA conference, 
the Association for Clinical Biochemistry conference (UK), and the American 
                                                
8
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Association of Clinical Chemistry Annual conference9.  It is hoped that the results will be 
published in a major international journal such as Clinical Chemistry or Journal of 





Training of research workers: 
Dr Omar will be the project leader. She is currently training as a Registrar in Chemical 
Pathology and is registered for the MMed Degree at UCT. The project will provide 
training in immunoassay techniques, including radioimmunoassay, ELISA and 
immunoblotting; and will be the basis for the dissertation towards the MMed degree. 
The project will form an adjunct for a collaboration with the University of Gotheborg in 
Sweden and will therefore be important for enhancing institutional capacity.   
 The long-term complications of HIV/AIDS, and the impact thereof in the South African 
context requires research investment.  This area has been poorly researched and has only 
emerged recently as larger numbers of patients are living longer as a result of HAART. 
  
A.9. INSTITUTIONAL APPROVAL 
 
This proposal has been submitted for ethics approval to the University of Cape Town 
Research Ethics Committee.  
                                                
9
 The findings of this research project were presented at the UCT Biomedical Research day, as well at a 
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Adiponectin ELISA kits from ALPCO 
Adiponectin RIA kit from Linco 
Adiponectin antibodies (Santa Cruz 
Biotechnology) 
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B. LITERATURE REVIEW 
B.1. OBJECTIVES 
The objectives of this literature review were to obtain the following background 
information: 
• The characteristics associated with the HAART-induced HIV-associated 
lipodystrophy syndrome 
• The mechanisms proposed for this lipodystrophy syndrome 
• Adiponectin: regulation, mechanism of action, link to HAART-induced HIV-
associated lipodystrophy 
 
B.2.  SEARCH STRATEGY AND QUALITY CRITERIA 
 
The literature search was performed using the Pubmed Central digital archive. The 
following keywords were used for the Pubmed search: HIV, lipodystrophy, HAART, 
adiponectin. Further relevant papers were identified from reference lists. One hundred 
and four articles were identified and used in this review. Articles were numerically 
referenced, according to their appearance in the review.  
 
B.3. SUMMARY OF LITERATURE 
B.3.1. Introduction 
The HIV epidemic is a major problem worldwide and more especially in sub-Saharan 
Africa. In South Africa, it was estimated that in 2008, 5.2 million (10.6%) South Africans 
were infected with HIV[1]. 
 
Currently, HIV therapy consists of a combination of highly active anti-retroviral therapy 
(HAART) drugs. These drugs can be divided into five classes, based on their mechanism 
of action, viz. nucleoside or nucleotide reverse transcriptase inhibitors (NRTIs), non-
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inhibitors and entry/fusion inhibitors (Figure 1). Anti-retroviral drugs operate via 
interruption of the viral replication cycle. Reverse transcriptase inhibitors prevent DNA 
formation from RNA and protease inhibitors inhibit the protease required for cleavage of 
nascent HIV proteins, preventing maturation and replication of the HIV virus. Integrase 
inhibitors and entry inhibitors prevent integration of viral genome into the human genome 
and entry of HIV into host cell, respectively. 
 
The South African National Department of Health has made available in the public 
sector, two HAART regimens. The first regimen consists of stavudine, lamivudine and 
either efavirenz or nevirapine i.e. a combination of two NRTIs and one NNRTI; while the 
second regimen consists of zidovudine (AZT), didanosine and lopinavir/ritonavir. AZT 
and didanosine are nucleotide- and nucleoside reverse transcriptase inhibitors, 
respectively, while liponavir/ritonavir is a protease inhibitor. 
 
 
Figure 1: Replication of HIV and inhibition by antiretroviral drugs. Pomerantz et al. Twenty years of therapy 
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B.3.2. HIV-associated lipodystrophy 
The advent of HAART has dramatically increased the life expectancy in HIV-infected 
patients[2, 3]. However, this increased life span has come at a metabolic price. A 
HAART-associated syndrome, resembling rare congenital and acquired forms of 
lipodystrophy syndromes,  was first described in the late 1990s[4] and is well 
documented[5-9]. This HIV-associated lipodystrophy syndrome comprises abnormal fat 
redistribution in the form of lipoatrophy (fat loss in the face, buttocks and extremities) 
and/or lipohypertrophy (excessive fat deposition in the abdominal (visceral fat 
accumulation), dorsocervical (buffalo hump) and breast regions and/or development of 
lipomata), as well as dyslipidaemia (hypertriglyceridaemia in particular, but also 
hypercholesterolaemia), insulin resistance (even type 2 diabetes mellitus) and lactic 
acidaemia[4, 7]. These patients therefore have increased visceral adipose tissue compared 
with subcutaneous adipose tissue, with insulin resistance related to the visceral and upper 
trunk adipose tissue[10]. The prevalence of lipodystrophy in HIV-infected individuals on 
HAART has been reported to be as high as 40% in developed countries[6, 8], with 
similar prevalences being reported in African studies - 30%[11], 34%[12] and 42.9%[13] 
in Tanzanian, Beninian, Rwandan and South African studies, respectively. In such 
patients, the prevalence of insulin resistance may be as high as 35%[14] compared with 
12% in HIV-infected patients naïve of therapy[15]. A causative link may therefore exist 
between protease inhibitor therapy and the development of diabetes mellitus. In fact, 
there have been reports of patients presenting with diabetes mellitus after 2 – 52 weeks of 
protease inhibitor therapy, with normalisation of glycaemia after cessation of 
treatment[16, 17].  
B.3.2.1. Risk factors for the development of lipodystrophy 
The lipodystrophy syndrome is predominantly associated with protease inhibitor therapy; 
however, treatment with thymidine analogues (stavudine and zidovudine) has also been 
implicated [18, 19]. Prolonged duration and combination-therapy with these drugs are 
associated with an increased risk for lipodystrophy, with clinical data suggesting that the 
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disturbances associated with the lipodystrophy syndrome[4]. Other risk factors include 
female gender, age and stage of the HIV disease[9].  
  
B.3.2.2. Underlying mechanisms causing lipodystrophy 
The mechanisms underlying the development of the constellation of metabolic 
abnormalities associated with HAART are poorly understood. Several factors are at play, 
causing mitochondrial dysfunction, impaired lipid metabolism and impaired functioning 
of adipocytes and endothelial cells. 
 
Role of protease inhibitors in the pathogenesis of lipodystrophy 
Protease inhibitors exert their anti-HIV action by inhibiting an HIV protease necessary 
for its maturation. The catalytic region of this enzyme is homologous to that found in two 
human proteins, viz. cytoplasmic retinoic-acid binding protein-1 (CRABP-1) and low 
density lipoprotein receptor-related protein (LRP)[4, 20]. Protease inhibitors also inhibit 
cytochrome P450 3A. CRABP-1 and cytochrome P450 3A are necessary in the 
conversion of retinoic acid to cis-9-retinoic acid, which in turn binds retinoid X receptor 
(RXR).  Protease inhibitors are thought to inhibit cis-9-retinoic acid formation and 
thereby, peroxisome proliferator activated receptor (PPAR) γ heterodimer formation with 
RXR. It is also thought to inhibit LRP, which normally, via the LRP-lipoprotein lipase 
complex, effects hepatic and endothelial clearance of triglycerides[20]. In addition, 
protease inhibitors inhibit steroid response element binding protein -1c (SREBP-1c), a 
key transcription factor and up-regulator of PPARγ[21]. The nett effect is increased 
adipocyte apoptosis and reduced adipocyte differentiation, which in turn leads to 
decreased triglyceride storage, hyperlipidaemia and insulin resistance[4, 5, 20].  
A genetic predisposition may play a role: An SREBP1c single nucleotide polymorphism 
has been shown to be predictive of HAART-associated hyperlipidaemia[22], with 
homozygosity for this polymorphism inversely associated with hyperinsulinism, 
hypercholesterolaemia and hyperglycaemia. Impaired adipocyte differentiation and 
adipocyte apoptosis caused by impairment of this gene product may be responsible for 
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(hypertriglyceridaemia and low level of high density lipoprotein (HDL)) may be linked to 
polymorphisms in the Apo CIII (inhibitor of liproprotein lipase) gene[23]. 
Protease inhibitors have also been shown to decrease CD36, a protein involved in the 
uptake of modified lipoprotein by macrophages and the transport of fatty acids in tissues 
with high metabolic capacity (responsible for up to 80% of uptake in the myocardium, 
skeletal muscle and adipocytes)[24]. Patients deficient in CD36 present with 
hyperlipidaemia and insulin resistance while in CD36 knock-out rodents, CD36 
administration improves the dyslipidaemia and insulin resistance.  
Insulin resistance may be further explained by another mechanism viz. altered expression 
of adipocytokines in adipocytes, with increased inflammatory cytokines such as tumour 
necrosis factor α (TNFα) and interleukin-6 (IL-6) (seen with specific protease inhibitors 
and with indinavir (a protease inhibitor), stavudine or zidovudine (both NRTIs)), and 
decreased adiponectin expression[21, 25]. Both TNFα and IL-6 have been causally linked 
to insulin resistance[26]. 
The role of protease inhibitors in the development of lipohypertrophy is not clearly 
understood. While the fat distribution is similar to that seen in patients with 
glucocorticoids excess, the hypothalamic-pituitary-adrenal axis in patients treated with 
protease inhibitors has not been shown to be disturbed[27]. Protease inhibitor-induced 
hyperinsulinism (by inhibition of insulin-degrading enzymes such as cathepsins) has been 
proposed as the initial trigger, leading to excess visceral adiposity, in turn leading to 
insulin resistance and hyperlipidaemia[27]. However, this hypothesis has yet to be proven 
experimentally. 
 
Role of NRTIs/NNRTIs in the pathogenesis of lipodystrophy  
Certain NRTIs are associated with the development of lipoatrophy, with the duration of 
treatment on these specific drugs adding to the risk for development of this condition. 
The thymidine analogues AZT and stavudine have been especially implicated, with 
stavudine introducing a two-fold greater risk than AZT for developing lipoatrophy, while 
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This lipoatrophy is thought to occur as a result of mitochondrial toxicity caused by the 
NRTI inhibition of mitochondrial polymerase γ (one of several enzymes and proteins 
essential in the replication of mitochondrial DNA (mtDNA)), leading to mitochondrial 
depletion (via decreased mtDNA content)[29]. mtDNA depletion has been demonstrated 
in subcutaneous adipose tissue in HIV-infected patients with lipodystrophy[30, 31]. This 
has been documented in particular with stavudine, correlating with the duration of 
exposure.  
Non-polymerase γ-related mechanisms have also been described, with AZT treatment, 
causing impairment of adenylate kinase and ADP/ATP translocase, as well as physically 
interfering with the mitochondrial membrane[32]. AZT inhibits the pre-adipocyte 
proliferation rate and clonal expansion, leading to disturbed adipocyte homeostasis and 
impaired adipogenesis[33]. AZT has also been linked to the development of features 
reminiscent of mitochondrial diseases which include ragged red fibres, decreased mtDNA 
and impaired mtDNA replication[33]. Evidence suggests that mitochondrial dysfunction 
precedes the onset of type 2 diabetes mellitus in insulin-resistant patients. These drugs 
may, therefore, cause insulin resistance directly in skeletal muscle through mitochondrial 
dysfunction and indirectly through adipocyte loss [34, 35]. In these patients, insulin 
resistance correlates with lactate levels and duration of NRTI therapy[35]. In contrast to 
protease inhibitors, NRTIs (specifically AZT and stavudine) have not been shown to 
increase IL-6 and TNFα expression[25].  
 
Nucleoside analogue reverse transcriptase inhibitors (stavudine more than zidovudine) 
are therefore associated with lipoatrophy while protease inhibitors are associated with 
metabolic complications such as dyslipidaemia and insulin resistance, having not been 
linked convincingly to the development of lipoatrophy[36]. 
 
B.3.3. Adiponectin 
As a consequence of the above perturbations in the adipocyte, patients with HIV-
associated lipodystrophy have low levels of the adipokine, adiponectin. This 30kDa 
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concentrations in the circulation (0.5 – 30µg/ml)[37]. Adiponectin is structurally related 
to complement factor C1q. It also shares structural similarity with several other proteins, 
including TNFα and C1q-TNF-related protein (CTRP)[38]. The adiponectin monomer 
comprises three structural domains, viz. the N-terminal variable domain, the collagenous 
domain and a globular C-terminal domain [38]. Adiponectin may exist in its globular 
(proteolytically cleaved) form or as the full-length form, although only the full-length 
form is present in the circulation[39]. Three predominant adiponectin forms occur in the 
circulation: low molecular weight (LMW) trimer, medium molecular weight (MMW) 
hexamer and high molecular weight (HMW) 12-18mer (Figure 2)[38]. Of these, the 
HMW form (greater than 669kDa) is considered the bioactive form[40]. The globular 
form has also been shown to possess biological activity, but it is found in relatively low 
concentrations[37]. Trimerisation of adiponectin monomers takes place at the globular 
domain (by hydrophobic interactions), but interaction (disulfide bonds) between the 
collagenous domains is required for larger homomultimers to be formed (when multiples 
of trimers assemble)[38, 40]. In addition to the hydrophobic and disulfide bonds required 
for multimerisation, post translational modifications are critical for the formation and 
stabilisation of the HMW form. This process involves hydroxylation, followed by 
glycosylation of amino acid residues (lysine and proline) in the collagenous domain[40].  
Impairment of this process has been demonstrated, both in vitro and in vivo, to lead to 
impaired intracellular assembly of HMW multimers and their secretion into the 
circulation[40]. This impairment translates into decreased adiponectin action, with low 
levels of glycosylated adiponectin demonstrated in type 2 diabetic patients compared 
with age and sex-matched controls[40]. Notably, these patients had decreased HMW to 
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Figure 2: Multimeric forms of adiponectin; LMW, MMW and HMW are the low, medium and high molecular 
weight forms of adiponectin, respectively. Kadowaki et al. Adiponectin and adiponectin receptors. Endo Rev  
2005; 26(3):439–451. 
B.3.3.1. Regulation of adiponectin synthesis and secretion 
Adiponectin is secreted predominantly by mature adipocytes, its production being 
increased 100-fold during adipocyte differentiation[41]. However, unlike other 
adipokines such as TNFα, adiponectin levels are lower in obese patients[42], with 
visceral fat mass correlating more with adiponectin levels than subcutaneous fat[37]. 
Moreover, secretion of adiponectin is lower in large than in small adipocytes[37]. 
The adipocyte is also the major determinant of the relative proportions of each of the 
adiponectin complexes in the circulation. With reduced adiponectin production in 
adipocytes, assembly and secretion of the HMW multimer is reduced, with consequent 
low levels in the circulation[43].  
Adiponectin production is upregulated during adipogenesis, being enhanced by 
adipogenic transcription factors such as PPARγ, CCAAT-enhancer-binding protein 
(C/EBP)α, C/EBPβ, Forkhead box O1 (FOXO1) and sirtuin (SIRT)1 (Figure 3)[37]. 
PPARγ, a nuclear receptor also involved in lipid and carbohydrate metabolism, binds a 
PPAR response element in the promoter of the adiponectin gene, causing upregulation of 
its secretion. Thus, PPARγ agonists, thiazolidinediones, upregulate adiponectin secretion, 
while PPARγ-knock-out mice have reduced adiponectin levels[44]. 
Additionally, adiponectin synthesis and secretion is inhibited by glucocorticoids, growth 
hormone, the pro-inflammatory factors TNFα, IL-6, C-reactive protein (CRP), activation 
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angiotensin system (angiotensin converting enzyme and angiotensin receptor antagonists) 
[37, 45, 46]. The effect of insulin on adiponectin secretion is poorly understood, with in 
vitro studies suggesting a positive relationship between adiponectin and insulin (thought 
to be via inhibition of the inhibitory effect of FOXO1 on PPARγ activation), while in 
vivo studies have shown a negative relationship between adiponectin and insulin[46]. 
Testosterone inhibits adiponectin secretion post translationally, and females therefore 
have higher levels of all fractions of adiponectin, in particular, the HMW form[40, 42]. 
Furthermore, HMW adiponectin levels increase with age[47]. Certain lifestyle  factors 
may also influence adiponectin levels, including diet – soy protein, fish oils and linoleic 
acid increase adiponectin levels, while high carbohydrate diets are associated with lower 
adiponectin levels[48].  
 
Figure 3: Diagram showing regulation of adiponectin at the gene level. Many factors stimulate or suppress 
adiponectin transcription, as is shown here. Liu et al. Transcriptional and post-translational regulation of 
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B.3.3.2. Metabolic and anti-inflammatory effects of adiponectin 
Adiponectin receptors 
Adiponectin initiates its actions by binding to one of two adiponectin receptors, AdipoR1 
and AdipoR2, integral membrane proteins that inversely resemble G-protein coupled 
receptors[49].  AdipoR1 is expressed ubiquitously (and is abundant in skeletal muscle), 
while AdipoR2 is predominantly expressed in the liver. While AdipoR1 has a high and 
low affinity for the globular and full-length adiponectin forms, respectively, AdipoR2 has 
intermediate affinity for both globular and full-length HMW adiponectin[50]. Moreover, 
AdipoR1 initiates the AMP kinase pathway (described later) and AdipoR2 the PPARα 
pathway (also described later)[51]. These receptors are reduced in type 2 diabetic 
patients, and correlate with insulin sensitivity in non-diabetic individuals[48]. Their 
expression is increased during fasting, and decreased during refeeding, correlating with 
insulin levels. In fact, insulin administration to hepatocytes in vitro suppresses expression 
of adiponectin receptors (via the phosphatidylinositol 3-kinase branch of the insulin 
signalling pathway)[52]. A third receptor for adiponectin (specifically the HMW form), 
T-cadherin, is expressed in injured vascular endothelial and smooth muscle cells at sites 
of atherosclerosis, and may be linked to the anti-atherosclerotic actions of 
adiponectin[50]. The signalling pathways involved have yet to be elucidated.  
Insulin sensitising actions of adiponectin via AMP kinase 
Adiponectin is an insulin-sensitising hormone. In rodent models, both recombinant 
adiponectin administration and adiponectin over-expression lead to improved insulin 
sensitivity, lowering glucose levels[53, 54].  
This insulin-sensitising action may occur via phosphorylation and activation of AMP-
dependent protein kinase (AMPK). In skeletal muscle, apart from phosphorylating acetyl 
coenzyme A carboxylase and leading to fatty acid catabolism (β oxidation), this also 
increases glucose utilisation and glucose transporter 4 (GLUT4) translocation to the cell 
membrane, thereby increasing glucose uptake. In the liver, AMPK activation leads to a 
reduction in the stimulation of the gluconeogenic enzymes phosphoenolpyruvate 
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Insulin sensitising actions via activation of PPARα 
Adiponectin was shown to activate PPARα, leading to upregulation of PPARα target 
genes (CD36, acyl-coenzyme A oxidase and uncoupling protein 2)[56]. CD36 and acyl-
coenzyme A oxidase are involved in fatty acid transport and catabolism, while 
uncoupling protein 2 causes energy dissipation. Activation of PPARα therefore leads to 
increased fatty-acid breakdown and energy consumption, leading to decreased 
triglyceride content in the liver and skeletal muscle[56]. As elevated tissue triglyceride 
content is known to cause insulin resistance by interfering with the insulin signalling 
cascade, this decrease leads to improved insulin sensitivity. 
 
The insulin-sensitising action of adiponectin may also be due to its enhancement of the 
buffering capacity of subcutaneous adipose tissue, leading to decreased ectopic fat 
deposition and therefore decreased lipotoxicity. This has been shown in leptin-deficient 
mice, with adiponectin administration causing subcutaneous adipose tissue expansion 
while adiponectin deletion is associated with increased hepatic fat deposition [57, 58].  
Anti-atherosclerotic action of adiponectin 
Adiponectin exerts its cardio-protective action through its anti-atherosclerotic and anti-
inflammatory actions. It has been shown to inhibit adhesion molecule expression, 
including E-selectin, vascular cellular adhesion molecule (VCAM)-1 and intracellular 
adhesion molecule (ICAM)-1. Adiponectin also inhibits inhibitor of nuclear factor-κB 
(IκB) phosphorylation, thereby inhibiting TNFα–induced nuclear factor-κB 
activation[39]. This may be the mechanism for preventing monocyte adhesion to 
endothelial cells. Furthermore, adiponectin suppresses the uptake of oxidised low density 
lipoprotein (LDL) by macrophages by inhibiting expression of the scavenger receptor 
class A-1 receptor, thereby inhibiting foam cell formation, and thus reducing vascular 
wall lipid accumulation. Moreover, adiponectin increases the HDL-mediated efflux of 
cholesterol from these cells[39, 59]. Adiponectin also inhibits platelet aggregation and 
thrombus formation[60]. In addition, by suppression of the production of certain growth 
factors (including heparin-binding epidermal growth factor-like growth factor, platelet-
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proliferation and migration of vascular smooth muscle cells, suppressing neointimal 
thickening[61]. Furthermore, through AMPK signalling, adiponectin promotes 
angiogenesis in response to ischaemia-induced injury[62]. Finally, adiponectin, via 
AMPK activation, suppresses the oxidized LDL-induced excessive  mitochondrial 
generation of reactive oxygen species (ROS), as well as hyperglycaemia-induced 
production of ROS[63]. Together, these actions inhibit atherosclerotic plaque formation. 
 
B.3.3.3. Adiponectin in the clinical scenario 
In accordance with the mechanisms outlined above, adiponectin levels are reduced in 
patients with obesity (particularly visceral obesity), insulin resistance, metabolic 
syndrome, type 2 diabetes mellitus, dyslipidaemia, coronary artery disease (CAD) and 
hypertension[48]. In fact, low adiponectin levels may predict the development of insulin 
resistance and progression to type 2 diabetes mellitus[48] and hypertension[64], while 
high adiponectin levels are associated with a lower risk of myocardial infarction, 
independent of CRP[65]. Adiponectin levels are also elevated in type 1 diabetes patients, 
severely insulin-resistant patients and those with antibodies against the insulin receptor, 
once again suggesting that insulin and its signalling pathway influence adiponectin 
sensitivity and levels[66]. Furthermore, single nucleotide polymorphisms in the 
adiponectin gene are associated with the metabolic syndrome, type 2 diabetes mellitus, 
increased body mass index (BMI), dyslipidaemia, increased waist circumference, raised 
blood pressure and coronary artery disease[45].  
 
Adiponectin levels correlate inversely with insulin resistance and CRP, apolipoprotein 
(apo) B, apo E and triglyceride levels, and positively with HDL and apo A levels[48, 67, 
68]. Moreover, adiponectin correlates negatively with the pro-inflammatory marker 
TNFα. 
 
B.3.3.4. HMW adiponectin 
The HMW form of adiponectin activates AMPK with a higher potency than the other 
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of total adiponectin measurement as an indicator in the assessment of insulin 
sensitivity[70]. Mutations in the collagen domain, which prevent HMW formation, are 
associated with altered AMPK activation and diabetes[71], while administration of HMW 
adiponectin to insulin-resistant adiponectin-deficient mice is associated with a reduction 
in glucose levels[72]. Both total and HMW adiponectin forms (and the HMW to total 
adiponectin ratio) increase with weight reduction[73].  
Both total and HMW adiponectin forms (and the ratio) correlate positively with HDL and 
fibrinogen and negatively with triglycerides, BMI, homeostasis model assessment of 
insulin resistance (HOMA-IR) and CRP[74]. HMW adiponectin and the ratio to total 
adiponectin are also lower in patients with hyperinsulinaemia, type 2 diabetes mellitus 
and CAD, correlating with the degree of CAD in men [74-77]. The association with type 
2 diabetes mellitus is stronger with HMW than with total adiponectin[78]. Furthermore, 
both HMW-adiponectin and the ratio are independent risk factors for the development of 
type 2 diabetes mellitus[79].  
Administration of thiazolidinediones causes increased HMW to adiponectin ratios, which 
correlate better with improved insulin sensitivity than do total adiponectin levels[80]. 
Furthermore, improvements in insulin sensitivity associated with gastric bypass surgery 
and weight loss also correlate better with HMW adiponectin than with total 
adiponectin[44, 73, 80]. The HMW to total adiponectin ratio (also called the adiponectin 
sensitivity index) was shown to be a better predictor for insulin resistance and the 
metabolic syndrome than total adiponectin[81, 82]. The ratio also correlates more 
significantly than total adiponectin with glucose and insulin levels[83].  
Together, these findings suggest that measurement of HMW adiponectin (and its ratio to 
total adiponectin) may be more relevant in predicting insulin resistance. 
B.3.3.5. Measurement of adiponectin isoforms 
Adiponectin isoform levels have been analysed using various cumbersome methods[84]. 
These include gel filtration chromatography, velocity gradient centrifugation, sodium 
dodecyl sulphate polyacrylamide (non-denaturing) gel electrophoresis and Western blot 
analysis. These methods are time-consuming and demand specific instrumentation and 
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recent, much simpler method involves the quantification of the different adiponectin 
isoforms by ELISA (using monoclonal antibodies), following a pre-treatment step with 
two proteases (protease A Amano digests LMW adiponectin alone, while protease K 
digests LMW and MMW adiponectin)[85]. This allows for the direct measurement of 
total and HMW adiponectin, and the indirect calculation of LMW and MMW adiponectin 
levels in approximately 4 hours[84].  
B.3.4. Adiponectin in HIV 
Due to adipose tissue redistribution and the associated metabolic disturbances 
characteristic of HIV-associated lipodystrophy, it is not surprising that there is a focus on 
adipocyte-secreted hormones such as adiponectin. In HIV-associated lipodystrophy, 
visceral adipose tissue is highly predictive of whole body glucose disposal, and this is 
possibly mediated by adiponectin as it correlates with both visceral adiposity and glucose 
disposal[86]. Adiponectin levels, both total and HMW, are decreased in such patients. In 
fact, total adiponectin levels in male patients with HIV-associated lipodystrophy are 50% 
that of patients without lipodystrophy and 25% of subjects without HIV[87]. Adiponectin 
in these patients correlates with measures of fat distribution, in line with its relationship 
to visceral adiposity[87]. In addition, it also correlates with insulin sensitivity (correlating 
positively with the qualitative insulin-sensitivity check index (QUICKI) and negatively 
with BMI, waist: hip ratio (WHR), fasting and 2h glucose and insulin, as well as 
triglycerides, apoB/A1 and CRP)[88]. Adiponectin levels are lower in HIV-infected 
patients who have high triglyceride levels than in those who have low triglyceride 
levels[89]. Adiponectin also correlates positively with HDL levels and negatively with C-
peptide levels in HIV-associated lipodystrophy[90]. Patients on both stavudine (an NRTI) 
and protease inhibitors, have significantly lower adiponectin levels (and significantly 
lower insulin sensitivity parameters (QUICKI)) than those not treated with stavudine[88]. 
Both protease inhibitors and NRTIs cause a decrease in adiponectin expression in murine 
adipocytes, this decrease being most profound with the protease inhibitors, ritonavir and 
saquinavir[25].  
In human subcutaneous adipocytes, adiponectin mRNA expression is significantly lower 
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adiponectin levels[90]. This is also true for patients receiving protease inhibitors when 
compared to those not receiving protease inhibitors[91]. Adiponectin may play an 
instrumental role in the pathogenesis of this syndrome, since protease inhibitor 
administration to mice caused a dose- and drug-related reduction in adiponectin[92]. The 
resulting dyslipidaemia in these mice was ameliorated upon treatment with recombinant 
adiponectin[92]. 
The protease inhibitor ritonavir accumulates in adipocytes where it inhibits preadipocyte 
development into mature adipocytes, down-regulating expression of PPARγ and 
adiponectin, while up regulating TNFα and IL-6 expression[93].  
Thiazolidinediones-induced improvement in insulin sensitivity in patients with HIV-
induced lipoatrophy and insulin resistance is associated with a concomitant increase in 
adiponectin levels, in line with the increase in total body and subcutaneous fat also seen 
in these patients[94]. HMW adiponectin is significantly increased [95], with 
thiazolidinediones therapy increasing the HMW to total adiponectin ratio more 
significantly than total adiponectin, even before any significant change in body fat 
distribution is evident[96]. This treatment is also associated with increased expression, in 
subcutaneous fat, of adiponectin mRNA, PPARγ mRNA and PPARγ coactivator 1 
(PGC1) mRNA, and decreased expression of IL-6 mRNA[97].  
Furthermore, HMW adiponectin expression (as is the case with total adiponectin) is 
decreased in mature murine adipocytes treated with efavirenz (an NNRTI) or either of the 
protease inhibitors ritonavir or nelfinavir. Interestingly, this decrease is reversed by 
changing to atazanavir (a different type of protease inhibitor). HMW adiponectin is also 
significantly lower in HIV-infected patients after starting HAART compared with before 
HAART therapy (excluding atazanavir). This decrease is reduced upon the introduction 
of atazanavir to therapy, accompanied by an improvement of the dyslipidaemia[98] seen 
in these patients, suggesting that not all protease inhibitors induce the metabolic changes 
found in the lipodystrophy syndrome. 
Although HMW (and its ratio to total) adiponectin is regarded as the most sensitive 
marker of insulin sensitivity, very little research has been done on the levels of this 
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on combination therapy that include protease inhibitors compared to those not on 
protease inhibitors).  
 
B.3.5. HIV-associated lipodystrophy and the risk for CAD 
Acute coronary syndromes are seen increasingly in HIV-infected patients receiving 
HAART (particularly protease inhibitors), the incidence of myocardial infarction related 
to longer exposure to combination drugs[99]. HIV itself may also contribute to 
cardiovascular risk, with one study demonstrating increased cardiovascular events in 
patients receiving episodic HAART (based on CD4 count) when compared with those 
receiving continuous therapy (hazard ratio 1.6, p=0.05)[100]. Apart from the decreased 
adiponectin levels (correlating with cardiac flow reserve), HIV-infected patients have 
other risk factors associated with cardiovascular disease [101, 102]. The presence of 
raised triglycerides and total cholesterol, as well as diabetes in these patients, is 
associated with a greater risk for presenting with myocardial infarction[99]. Furthermore, 
the decreased HDL levels, leading to decreased efflux of cholesterol from macrophages; 
and endothelial dysfunction seen in these patients, both promote atherosclerosis[103]. In 
fact, a large study reported a 16% relative increase in the incidence of myocardial 
infarction per year of HAART exposure, explained mainly by the hypercholesterolaemia, 
hypertriglyceridaemia and low HDL cholesterol[104]. 
 
B.3.6. Conclusion and needs for future research 
Insulin resistance is a prominent feature of the HIV-associated lipodystrophy syndrome. 
It is evident that decreased adiponectin, specifically its HMW form, is a major 
contributor to the development of insulin resistance, and may be partly responsible for the 
increased risk of developing CAD (through reduced anti-atheresclerotic actions), having 
been demonstrated to correlate with the extent of CAD. Furthermore, it has been shown 
to be a superior marker to total adiponectin for the detection and assessment of insulin 
resistance. Many studies have assessed total adiponectin levels in patients on HAART. 
However, very few studies have assessed the levels of the HMW form (and its ratio to 
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This project seeks to assess the levels of HMW adiponectin (and its ratio to total) in HIV-
infected patients receiving HAART including protease inhibitors, comparing these levels 
to those in patients receiving HAART without protease inhibitors, and to those in patients 
not receiving HAART.   
Word count: 4296 
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C.2. ABSTRACT 
Background 
Our current HIV-treatment regimens consist of highly active antiretroviral therapy 
(HAART) regimens 1 (nucleotide reverse transcriptase inhibitors (NRTIs) only), and 2 
(protease inhibitors (PI) and NRTIs). HAART is associated with the lipodystrophy 
syndrome, insulin resistance and reduced total adiponectin (TA) levels. The high 
molecular weight (HMW):TA ratio is a superior marker of insulin resistance.  
Objectives 
To establish whether HMW:TAs are lower in patients on PIs and whether findings 
correlate with insulin resistance and dyslipidaemia. 
Methods 
66 HIV-infected females were recruited: 22 on regimen 2 (PI group), 22 on regimen 1 
(non-PI) and 22 treatment naïve (TN), matched for BMI and age. Patients with a history 
of diabetes or impaired glucose tolerance were excluded. Serum adiponectin multimers 
were analysed using the AlpcoTM Adiponectin (Multimeric) enzyme immunoassay. 
Lipodystrophy score, calf skin-fold thickness, waist hip ratios (WHR), lipids, glucose and 
insulin were assessed and HOMA-IR and QUICKI calculated. Data were analysed non-
parametrically and multivariate analysis was performed.  
Results 
TA and HMW levels were lower in the treatment groups than in the TN group. HMW:TA 
was lower in the PI than in the non-PI and TN groups, and in the non-PI than in the TN 
groups. HMW:TA correlated negatively with waist, insulin and HOMA-IR, and 
positively with QUICKI, independently of BMI.  Triglycerides and cholesterol were 
significantly higher in the treatment groups than in the TN group. 
Conclusion 
HMW:TA is significantly decreased with HAART (particularly with PIs) and may be 
linked to the development of  lipodystrophy in these patients. 
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C.3. LIST OF ABBREVIATIONS 
LMW, low molecular weight; MMW, medium molecular weight; HMW, high 
molecular weight; NFκB, nuclear factor κB; HIV, human immunodeficiency virus; 
HDL, high density lipoprotein; PI, protease inhibitor; d4T, stavudine; AZT, zidovudine; 
PPARγ, peroxisomal proliferator activated receptor γ; HAART, highly active 
antiretroviral therapy; 3TC, lamivudine; EFV, efavirenz; ddI, didanosine; LPV/r, 
liponavir/ritonavir; TA, total adiponectin; ARV, antiretroviral; non-PI, non-protease 
inhibitor; BMI, body mass index; TN, treatment naive; WHR, waist: hip ratio; HOMA-
IR, homeostatic model assessment for insulin resistance; QUICKI,  quantitative insulin-
sensitivity check index; CD4, cluster of differentiation 4; CV, coefficient of variation; 




Adiponectin is an insulin-sensitising hormone[1, 2] found in three major multimeric 
forms in the circulation viz. the low molecular weight (LMW) trimer, the medium 
molecular weight (MMW) hexamer and the high molecular weight (HMW) 16-18mer 
(>400kDa). Adiponectin is present at relatively high concentrations in healthy 
individuals, making up approximately 0.05% of the total serum protein[3], with the 
HMW form the predominant and active form of adiponectin[4]. Sexual dimorphism 
exists, with females exhibiting higher circulating levels of adiponectin (total and HMW) 
than males[5-8]. 
Apart from its insulin-sensitising effects through increased fatty acid oxidation in muscle 
and liver and inhibition of gluconeogenesis [1, 2], adiponectin also exhibits anti-
inflammatory and anti-atherosclerotic actions through inhibition of tumour necrosis 
factor-alpha (TNF α)-induced nuclear factor kappaB (NFkB) activation[9],  adhesion 
molecule expression[10, 11], and class A scavenger receptor expression in macrophages, 
thereby inhibiting foam cell formation[12].  
Although an adipokine, unlike other hormones secreted by adipocytes, adiponectin levels 
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been shown to increase total adiponectin, HMW adiponectin and the HMW to total 
adiponectin ratio. Low adiponectin levels are seen in patients with insulin resistance, type 
2 diabetes mellitus and atherosclerosis as well as in patients with lipoatrophy and 
lipohypertrophy[13-15], with HMW adiponectin shown to correlate better with insulin 
sensitivity than total adiponectin[16] and the HMW: total adiponectin ratio to be a better 
predictor of coronary artery disease than total adiponectin[17]. This ratio has been shown 
to be suppressed in type 2 diabetes mellitus patients with coronary artery disease even 
when HMW and total adiponectin levels were unchanged[18].  
In HIV-associated lipodystrophy, a syndrome consisting of fat redistribution (central 
hypertrophy and  lipoatrophy of facial region and extremities), dyslipidaemia 
(particularly hypertriglyceridaemia) and insulin resistance, adiponectin levels are 
significantly lower, demonstrating a negative correlation with abdominal visceral fat 
mass, serum triglycerides and insulin resistance and a positive correlation with high 
density lipoprotein (HDL) and extremity fat[19, 20]. This syndrome is associated with 
antiretroviral (ARV) therapy, particularly protease inhibitors (PIs) (but also thymidine 
analogues such as stavudine (d4T) and zidovudine (AZT)) [21, 22]. In such patients, 
thiazolidinedione administration, via peroxisome proliferator-activated receptor γ 
(PPARγ) activation, leads to improved insulin sensitivity[23] with upregulation of 
adiponectin levels, specifically the HMW form[24, 25], while in mice, adiponectin 
administration markedly ameliorates protease-induced dyslipidaemia, suggesting that 
hypoadiponectinaemia may be partially responsible for the metabolic derangements 
associated with PIs[26].  
In South Africa, the National Department of Health made available to HIV-infected 
patients, two highly active antiretroviral therapy (HAART) regimens. The first regimen 
consists of d4T, lamivudine (3TC) and either efavirenz (EFV) or nevirapine i.e. a 
combination of two nucleotide reverse transcriptase inhibitors (NRTIs) and one non-
nucleotide reverse transcriptase inhibitor (NNRTIs); while the second regimen consists of 
AZT, didanosine (ddI) and lopinavir/ritonavir (LPV/r). AZT and ddI are nucleotide- and 
nucleoside reverse transcriptase inhibitors, respectively, while LPV/r is a PI, inhibiting 
the protease required for cleavage of nascent HIV proteins and therefore maturation and 
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The purpose of this study was to establish whether the HMW: total adiponectin (TA) 
ratio is lower in HIV-infected patients receiving PI therapy compared with those not 
receiving PIs and whether these findings are associated with biochemical evidence of 




This study was performed in accordance with the Helsinki Declaration. A cross-sectional 
study was performed on subjects recruited from the ARV roll-out clinic at Groote Schuur 
Hospital, after departmental and ethics approval was obtained from the University of 
Cape Town. Sixty-six HIV-infected African females were enrolled into the study into 
three groups, viz. PI (Regimen 1 for at least six months), non-PI (Regimen 2 for at least 
six months) and treatment naïve (TN) groups, each consisting of 22 patients. The subjects 
in the PI group were recruited consecutively from the clinic, while the subjects in the 
other two groups were matched to the PI group for body mass index (BMI) and age. The 
TN group of patients were patients who had been referred to the ARV clinic for 
enrolment onto ARVs. Written informed consent was obtained from each patient and 
history taken regarding medical conditions, ARV therapy and other drug therapy. Bloods 
were drawn prior to their commencement on ARVs. Exclusion criteria included a history 
of impaired glucose tolerance or diabetes mellitus, active acute opportunistic infections, 
renal failure and pregnancy. Subjects were given a lipodystrophy questionnaire[27] 
relating to their perceived change of fat distribution in seven regions (face, arms, legs, 
buttocks, breasts, abdomen and neck) and were scored for atrophy or hypertrophy as 
follows: 0 = none, 1 = mild, 2= moderate and 3= severe. The total lipodystrophy score 
was then calculated as the sum of the individual scores for the seven regions. Body 
circumferences (waist and hip), weight, height and calf skin-fold thickness were 
measured as described previously[28] (briefly described in Supplemental Data),  and the 
BMI and waist: hip ratio (WHR) were calculated. Fasting bloods were drawn for the 
measurement of total cholesterol, HDL, triglycerides, insulin and multimeric adiponectin 
in serum, as well as glucose levels in plasma. Samples were separated within 2 hours and 
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glucose) was performed and 2-h glucose measured. Thereafter, the homeostatic model 
assessment for insulin resistance (HOMA-IR) and quantitative insulin-sensitivity check 
index (QUICKI) were calculated. CD 4 count results were obtained from the hospital 
clinical records.   
Adiponectin was analysed using the AlpcoTM Adiponectin (Multimeric) enzyme 
immunoassay (sensitivity 0.04ng/mL and coefficient of variation (CV) <15%), insulin by 
Bayer ACS180 auto-analyser (CV 12 %), and the rest of the chemistry analytes using the 
Bayer Alera chemistry analyser. 
 
Statistical analysis 
Results were analysed non-parametrically, using the Mann-Whitney U, Kruskall-Wallis 
and Spearman correlation tests. Multivariate analyses and power calculations were 
performed. A p-value of 0.05 was considered significant. Analyses were performed using 





In the PI group, 21 patients were receiving LPV/r and one Atazanavir for at least six 
months. The median duration on PIs was 11.5 months, while the median duration on 
regimen 1 drugs prior to progression to regimen 2 was 15 months (Table 2). Four (18%) 
patients were receiving d4T and 13 (59%) AZT as part of their regimen. The median 
durations on these drugs were 15.5 and nine months, respectively. Twenty of the 22 
patients were currently receiving PIs when the study was commenced, while two patients 
had been off PIs for 2 and 2.5 months, respectively. For these two patients the durations 
on PIs were 30 and 6 months, respectively. In the non-PI group, 21 of the 22 patients 
were receiving either AZT or d4T, with the median durations on d4T and AZT 10 and 12 
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of the drug combinations shown in Table 1. None of the patients were receiving lipid-
lowering therapy. 
  
The CD 4 count was significantly higher in the PI than in the non-PI and TN groups 
(Table 2). It was also significantly higher in the non-PI groups than in the TN group 
(Table 2). 
 
The median (inter-quartile range) age and BMI among the groups were 36 (29; 42) years 
and 27 (24; 30), respectively (medians and inter-quartile ranges for the individual groups 
are shown in Table 3). Waist measurement, calf skin-fold thickness and WHR did not 
differ among the groups (Table 3).  
 
While neither the total lipodystrophy score nor its hypertrophy portion differed 
significantly among the groups, the atrophy portion was significantly higher in the PI 
group than in the non-PI group (p =0.01134 ) (Supplemental Data Table 1). However, it 
did not differ between the PI and TN or non- PI and TN groups. 
In the PI group, 5 (23%) patients described facial, 5 (23%) arm and 8 (36%) leg atrophy, 
while no patients described fat deposition in the neck or dorso-cervical areas, although 5 
(23%) patients described deposition in the abdomen, 2 (9%) in the buttocks, 6 (27%) in 
the breasts and 4 (18%) mentioned the presence of lipomata. In addition, 3 (14%) 
described fat deposition in the facial region. The lipodystrophy score distribution for the 
other groups can be seen in Supplemental Data Table 2. 
 
Adiponectin levels in serum 
Total adiponectin levels were within the reference interval for women (3.5 – 22mg/L)[29] 
in all groups, however, they were significantly lower in both treatment groups than in the 
TN group (p = 0.0299 and 0.0290, respectively) (Figure 1 and Table 3). HMW 
adiponectin levels were also significantly lower in the treatment groups when compared 
with the TN group (p = 0.0005 and p < 0.0001, respectively) (Figure 1 and Table 3). 
However, for both total and HMW adiponectin levels, no statistically significant 
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Data Table 3). In contrast, the HMW: total adiponectin ratio differed significantly among 
the groups (p<0.0001) and was significantly lower in the PI group than in both the non-PI 
(p = 0.0019) and the TN (p<0.0001) groups (Figure 1, Table 3 and Supplemental Data 
Table 3). The non-PI group also had significantly lower ratios than the TN group (p = 
0.0167).  
While the LMW adiponectin fraction did not differ among the groups, its ratio to total 
adiponectin was significantly higher in both the PI and non-PI groups than in the TN 
group (p = 0.0004 and 0.0095, respectively) (Figure 1, Table 3 and Supplemental Data 
Table 3). The MMW adiponectin was similar among the groups (Supplemental Data 
Table 1).  
Traditional markers of insulin resistance and dyslipidaemia 
There were no statistically significant differences among the groups for insulin, fasting 
and 2-h glucose or the derived parameters HOMA-IR and QUICKI (Table 3). However, 
in the entire group of HIV-infected patients, the 15 (23%) patients with HOMA-IR > 1.95 
had significantly lower (p=0.0059) HMW: total adiponectin ratios (median 0.31, IQR 
0.22 and 0.47) than those with lower HOMA-IRs (median 0.50, IQR 0.40 and 0.57) 
(Figure 2). Similarly, 40 (60%) of the entire group of HIV-infected patients had a BMI ≥ 
25. These patients had significantly lower (p=0.0475) HMW: total adiponectin ratios 
(median 0.44; IQR 0.31 and 0.54) than those with lower BMIs (median 0.50, IQR 0.44 
and 0.58).  
Both fasting cholesterol and triglyceride levels were significantly higher in the PI and 
non-PI groups than in the TN group (p = 0.0072 and 0.0020, respectively, for cholesterol, 
and 0.0037 and 0.0133, respectively, for fasting triglyceride levels) (Table 3 and 
Supplemental Data Table 3). However, both of these analytes were well within normal 
limits. In fact, triglyceride concentrations were low in the TN group.  HDL and LDL 
cholesterol levels were also significantly higher in the non-PI group than in the TN 
groups, but did not differ significantly between either the PI and non-PI groups or 
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Correlates of adiponectin 
In the entire HIV- infected cohort (n = 66), the following relationships were found: 
HMW, total adiponectin, and their ratio had a significant negative correlation (p <0.05) 
with waist, BMI, fasting insulin, HOMA-IR, fasting triglycerides and CD 4 count, while 
they had a significant positive correlation (p<0.05) with QUICKI (Table 4). The same 
was true for MMW and the opposite true for the LMW: total adiponectin ratio (Table 4 
and Supplemental Data Table 4). Interestingly, the LMW adiponectin correlated 
significantly negatively (p < 0.05) with the 2-h glucose level and positively (p < 0.05) 
with total and HMW adiponectin levels, individually. LMW adiponectin levels on their 
own did not correlate significantly with fasting insulin, fasting glucose, HOMA-IR, 
QUICKI, lipid levels, lactate or CD 4 count. 
 
In addition to the above-mentioned findings, waist measurement correlated significantly 
positively (p < 0.05) with calf skin-fold thickness, BMI, fasting insulin, HOMA-IR, 
fasting triglyceride and CD 4 count, and negatively (p < 0.05) with QUICKI 
(Supplemental Data Table 4). Furthermore, fasting insulin and HOMA-IR correlated 
significantly positively (p < 0.05) with BMI, while the opposite was true for QUICKI.  A 
positive correlation (p < 0.05) was also observed between fasting triglyceride and BMI, 
waist, 2-h glucose and fasting total cholesterol, and between calf skin-fold thickness and 
BMI. A negative (but not significant) correlation was noted between triglyceride and calf 
skin-fold thickness measurement. Total, HDL and LDL cholesterol showed no significant 
correlation with any of the adiponectin fractions or ratios.  
 
The total lipodystrophy score correlated negatively (p < 0.05) with BMI and calf 
measurement, however, no significant correlation was seen between this score and waist 
measurement, glucose, insulin, HOMA-IR, QUICKI, lipids or adiponectin fractions 
(Supplemental Data Table 4). The atrophy portion of the score correlated negatively with 
the BMI, LDL and HDL, and positively (p < 0.05) with MMW: total adiponectin ratio. It 
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glucose, insulin, HOMA-IR, QUICKI or other adiponectin fractions and ratios. The 
hypertrophy portion did not correlate significantly with any of the variables.  
Multivariate analysis 
The negative correlations between total adiponectin, HMW: total adiponectin and HMW 
adiponectin, respectively, and waist, fasting insulin and HOMA-IR were still significant 
after multivariate analysis to adjust for BMI (p<0.05) (see Supplemental Data Tables 5-
7).   Furthermore, adjustment for BMI did not alter the significance of the difference 
between the groups for HMW: total adiponectin. Also, adjusting for BMI did not alter the 
significance of the positive correlation between HMW: total adiponectin and QUICKI, 
however, total and HMW adiponectin lost their significant correlation with QUICKI 
(Supplemental Data Table 8). The significant negative correlations between CD 4 count 
and total adiponectin, HMW: total adiponectin and HMW adiponectin were still evident 
after adjusting for duration of HAART (Supplemental Data Table 9), while the 
significance of the positive correlation initially seen between waist measurement and CD 
4 count by univariate analysis, was attenuated when multivariate analysis was performed 
to adjust for duration of HAART (Supplemental Data Table 10).  
The correlations seen in univariate analysis between LMW: total adiponectin and fasting 
insulin, HOMA-IR and QUICKI were still significant after multivariate analysis, 
adjusting for BMI; while the correlations between MMW adiponectin and fasting insulin, 
HOMA-IR and QUICKI, respectively, lost significance after adjusting for BMI 
(Supplemental Data Tables 11-13). 
 
Power analysis for major variables 
Adiponectin 
The study was sufficiently powered (83.4%) to detect a difference in HMW: total 
adiponectin of 0.10 (using 0.55 as the mean for patients not on HAART). [For a 
difference of 0.09, the power is 75.5%. A sample number of 30 would provide sufficient 
power (80%) to detect a difference of 0.09.] However, the study was not sufficiently 
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significantly different among the treatment groups. A larger study number (at least 
n=100) would be needed to confirm these findings. 
Fasting insulin  
The study is also not sufficiently powered (8%) to confirm that fasting insulin levels were 
not significantly different among the groups. A much larger group would need to be 




The HIV–associated lipodystrophy syndrome is characterised by the presence of body fat 
redistribution (consisting of subcutaneous adipose tissue loss primarily from the facial 
region and extremities and / or deposition of excess adipose tissue around the neck, 
dorso-cervical spine, upper torso and intra-abdominal region), dyslipidaemia (which 
includes hypercholesterolaemia, hypertriglyceridaemia and low HDL cholesterol) and 
insulin resistance[21]. This syndrome is primarily seen in HIV-infected patients on 
HAART, with a 17% risk of developing lipodystrophy after the first year of HAART and 
each additional 6 month period associated with a 45% risk.[30]. These findings are 
particularly associated with PIs, but similar findings have been seen in some patients on 
thymidine analogues such as d4T and AZT[22].  
In our patient samples, we did not demonstrate a difference in lipodystrophy score among 
the three treatment groups. This may be explained by the fact that the score was entirely 
subjectively provided by patients’ impression of whether they had lost or gained fat tissue 
in the various body regions. However, both calf skin-fold thickness (used as a surrogate 
for lipoatrophy in the extremities) and waist measurements (used as a surrogate for 
abdominal weight gain) also did not differ among the groups, giving some credibility to 
the lipodystrophy scores derived. As we matched the non-PI and TN groups to the PI 
group for age and BMI, a difference in the waist measurement or calf skin-fold thickness 
could have been a useful indicator of lipoatrophy or lipohypertrophy. This may possibly 
be explained by the relatively short duration on HAART (median 11.5 months in the PI 
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concentrations (high, total and their ratio) independently of BMI (Supplemental Data 
Table 5), and therefore, by implication, independently of weight. This may indicate a 
connection between adiponectin concentrations (especially HMW: total adiponectin as 
the correlation is most significant for this form of adiponectin) and the development of 
lipodystrophy.  
Furthermore, we demonstrated higher triglyceride and cholesterol concentrations in the 
treatment groups, independent of whether the patients were receiving PIs or not. 
Hypertriglyceridaemia is a recognized feature of the metabolic abnormalities associated 
with the lipodystrophy syndrome, and its inverse relationship with adiponectin is 
known[19]. However, in our study, fasting triglyceride levels were well within the 
reference interval, and may indicate improved health in response to HAART, rather than 
indicate progression to dyslipidaemia. In addition, we demonstrated a negative 
relationship between CD 4 count and adiponectin (HMW, total and their ratio), 
independent of the duration of HAART therapy (Supplemental Data Table 9), a 
relationship which requires furthers investigation before any inferences can be made. CD 
4 counts were, as expected, higher in patients receiving both PIs and NRTIs than in 
patients receiving no PIs; and higher in these patients than in those not receiving 
HAART.  
 
It is known that adiponectin levels in HIV-infected patients with HAART–associated 
lipodystrophy are substantially lower than in those without lipodystrophy or in uninfected 
patients[31]. In fact, adiponectin has been implicated in the pathogenesis of HIV– 
associated lipodystrophy[26]. PI administration produced dose-related reduction in 
adiponectin levels in mice, while administration of recombinant adiponectin ameliorated 
the associated dyslipidaemia in these mice. The subjects in our main study group have 
each been receiving PIs for at least six months, with the median duration on a PI drug 
being 11.5 months. In addition, some patients in this group have also been receiving 
either d4T or AZT (Table 2). It was, therefore, interesting to note that total adiponectin 
levels were well within the reference interval in all groups, however, they were 
significantly lower in HIV-infected patients on HAART therapy (both PIs and non-PIs) 
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The active form of adiponectin is the HMW fraction, having been shown to correlate 
better with insulin sensitivity than total adiponectin[32]. As such, HMW adiponectin has 
been shown to be low in HIV-infected patients with insulin resistance[24]. Our study 
revealed the presence of significantly lower HMW adiponectin levels in patients 
receiving both PIs and non-PIs, but also in those receiving only non-PIs. This finding in 
the latter group, may be attributed to the use of d4T (16 (66%) patients) or AZT (5 (23%) 
patients), which have both been associated with lipodystrophy[33]. The HMW: total 
adiponectin ratio is a superior marker of insulin resistance, having been shown to be a 
better predictor of insulin resistance in patients with the metabolic syndrome than total 
and HMW adiponectin levels individually[34]. It is also an independent risk factor for 
coronary vascular disease (CVD)[35]. Previous studies have shown increased 
cardiovascular risk in HIV-infected patients, including those on HAART[36, 37]. We 
found this ratio to be significantly lower in the PI and less so (but nevertheless still 
significantly so) in the non-PI groups, implying an increased risk for CVD in patients on 
HAART (with the risk for CVD increased when both PIs and non-PIs are being used), in 
line with the findings of others. This significantly lower HMW: total adiponectin ratio in 
patients receiving both PIs and NRTI (with the majority, i.e. 17 of 22, of patients also 
receiving a thymidine analogue) confirms the findings of others that protease inhibitors 
and thymidine analogues induce metabolic complications synergistically[21]. 
Our patient groups were selected to exclude the presence of overt diabetes, and therefore 
it was not surprising that fasting glucose was not abnormal in any of the groups. 
However, we did not expect to find the median fasting insulin and 2-h glucose (post oral 
glucose tolerance test) levels to be normal as well (Table 3). These markers of insulin 
resistance, as well as HOMA-IR and QUICKI, did not differ among the groups in our 
study, despite the difference in total and HMW adiponectin, and their ratio, among the 
groups. However, a larger (sufficiently powered) study sample is required to verify this 
lack of significant differences among the groups for these variables. Notwithstanding, the 
relationship between insulin resistance markers and adiponectin, previously shown[19], 
was demonstrated here, with HOMA-IR correlating negatively with adiponectin levels 
(high, total and their ratio) and QUICKI correlating positively with the HMW: total 
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correlated negatively with WHR, fasting insulin levels, BMI and triglyceride levels (all 
markers of insulin resistance). Furthermore, the HMW: total adiponectin ratio was 
significantly lower in patients (in all groups) with HOMA-IR greater than 1.95 (cut-off 
for insulin resistance[38]) than in those with HOMA-IR less than or equal to 1.95 and 
also significantly lower in patients with BMI greater than or equal to 25 than in those 
with lower BMIs.  
Interestingly, we also demonstrated that the LMW ratio to total adiponectin was 
significantly higher in patients receiving HAART (with patients on PI and NRTIs 
showing higher ratios than those not on PIs) than in treatment naïve HIV-infected 
patients. This increase may suggest that impaired multimerisation may be one of the 
mechanisms by which HAART therapy induces insulin resistance in HIV-associated 
lipodystrophy. Impaired multimerisation is known to be associated with decreased 




These data demonstrate that both PI- and non-PI-containing HAART regimens 
significantly lower the HMW: total adiponectin ratio in HIV patients, with the ratio more 
significantly decreased in the PI-containing regimen, implying that PIs and NRTIs have 
an additive effect on the HMW: total adiponectin ratio. Although the HMW: total 
adiponectin ratio correlated negatively with indirect markers of insulin resistance, no 
overt insulin resistance was demonstrated. The HMW: total adiponectin ratio may 
therefore be an earlier or more sensitive marker of insulin resistance in HIV-infected 
patients on HAART. Furthermore, the increased LMW: total adiponectin ratios seen in 
these patients may imply that impaired multimerisation may be a mechanism by which 
the HMW adiponectin is lowered. Further studies are required to confirm this.  
 
Limitations 
Due to funding restrictions, the sample size was limited to 22 in each group. The study 
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adiponectin levels did not differ significantly among the various groups. Further studies 
are required in a larger study group to confirm that the findings for these variables are not 
subject to Type II statistical error. The study group was also limited to females as, in 
South Africa, females more frequently present for medical attention and therefore very 
few male patients were available for recruitment to the study. Assessment of 
lipodystrophy in this study was not reliable as this was a cross-sectional study and 
therefore an objective assessment by a clinician could not be performed. The score 
provided was determined solely by patient self-assessment. Drug compliance and dietary 
history in the different groups were not formally assessed, and may have had some 
influence on adiponectin levels.  
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C.10. TABLES AND FIGURES 
PI Group non-PI Group 
LPV/r + ddI + AZT AZT + 3TC + Nevirapine 
LPV/r + 3TC + AZT AZT + 3TC + EFV 
LPV/r + EFV d4T + 3TC + Nevirapine 
LPV/r + Nevirapine d4T + 3TC + EFV 
LPV/r + Combivir Nevaripine + Combivir 
Atazanavir + 3TC + EFV  
 
Table 1: Antiretroviral drug combinations in the two treatment groups. PI, protease inhibitor; non-PI, non- 












Group Regimen 1 Regimen 2 d4T AZT CD 4 count 
 median (IQR) median (IQR) median (IQR) median (IQR) median (IQR) 
PI 15 (8.5 - 21.5) 11.5 (9.3 – 14.0) 15.5 (9.8 - 22.3) 9 (5 - 16.5) 465 (231 – 577) 
     p = 0.0416* 
non-PI 12 (9.5 – 20.0)  10 ( 8 - 17.5) 12 (11 – 15.0) 274 (186 – 352) 
     p = 0.0128** 
TN - - - - 171 (117 – 218) 
     p = 0.0002*** 
 
Table 2: Duration of therapy (months) and CD 4 counts (x 106 per litre) among the groups. PI, 
protease inhibitor group; non-PI, non- protease inhibitor group; d4T, stavudine; AZT, 
zidovudine; IQR, inter-quartile range; *= p-value indicating significant difference between PIs 
and non-PIs; **= p-value indicating significant different between non-PIs and TNs; *** = p-value 
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Age 34.5 34.5 35.5 years p = 0.9862 
 (24.7 – 30.7) (31 – 42) 28 – 42)   
Weight 69.6 65.3 60.9 kg p = 0.2463 
 (59.9-78.8) (59.2 – 77.6) (56.6 – 60.7)   
BMI 27.7 25 25.7  p = 0.5860 
 (24.7 – 30.7) (23.7 – 29,6) (22.7 – 29.8) -  
WHR 0.87 0.85 0.84 - p = 0.3148 
 0.82 – 0.93 0.78 -0.89 0.80- 0.90   
Waist 89.1 82.5 81.5 cm p = 0.1944 
 81.5 – 95.0 79.5 – 94.0 76.0 – 88.5   
Calf skin-fold thickness 16.5 15.3 17.5 mm p = 0.5836 
 8.9 – 21.2 10.8 – 19.1 11.2 – 22.6   
Total adiponectin 5.64 7.30 9.03 mg/L p = 0.0387 
 3.27 – 9.71 3.92 -8.70 7.58 – 12.12   
HMW adiponectin 2.23 3.49 5.29 mg/L p = 0.0015 
 0.99 – 4.01 1.77 -5.39 3.73 – 7.11   
HMW: total adiponectin 0.35 0.48 0.56 - p < 0.0001 
 0.29 – 0.42 0.40 -0.56 0.52 – 0.61   
LMW adiponectin 1.89 1.71 1.74 mg/L p = 0.7523 
 1.40 – 3.25 1.51 -  2.60 1.33 – 2.48   
LMW: total adiponectin 0.40 0.30 0.21 - p = 0.0005 
 0.28 – 0.53 0.24 - 0.40 0.16 – 0.28   
Fasting insulin 5.52 3.1 4.37 mIU/L p= 0.3648 
 2.62 – 10.12 2.1 -5.9 1.89 – 8.10   
Fasting glucose 4.8 5.1 5.1 mmol/L p= 0.1452 
 4.5 – 5.0 4.6 – 5.5 4.7 – 5.4   
HOMA-IR 1.18 0.72 1.05 - p = 0.4788 
 0.52 – 2.11 0.50 -1.19 0.39 – 1.75   
QUICKI 0.37 0.41 0.38 - p = 0.2339 
 0.33 – 0.42 0.37 – 0.433 0.35 – 0.46   
2hr glucose 5.8 5.2 5.2 mmol/L p = 0.8765 
 4.4 – 6.3 4.7 – 6.1 4.4 – 6.1   
Fasting total cholesterol 4.5 4.4 3.5 mmol/L p = 0.0033 
 3.8 – 5.4 4.2 – 5.3 3.0 – 4.4   
Fasting triglycerides 1.2 1.2 0.9 mmol/L p = 0.0065 
 0.9 – 1.8 0.9 – 1.4 0.7 – 1.1   
HDL 1.0 1.1 0.8 mmol/L p = 0.0426 
 0.8 – 1.2 0.9 – 1.4 0.6 – 1.1   
LDL (calculated) 2.5 2.8 2.2 mmol/L p = 0.0223 
 2.1 – 3.2 2.5 – 3.1 1.7 – 2.7   
Table 3: Median and inter-quartile ranges for the different variables in the three groups. P <0.05 demonstrates 
a significant difference for the variable among the groups. PI, protease inhibitor group; nonPI, non- protease 
inhibitor group; WHR, waist: hip ratio; HMW, high molecular weight; MMW, medium molecular weight; 
LMW, low molecular weight; HDL, high density lipoprotein, LDL, low density lipoprotein; KW, Kruskall-
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 Adiponectin fraction 
 Total HMW HMW: total MMW MMW: total LMW LMW : total 
Waist -0.5348 -0.5518 -0.4836 -0.5058 ns ns 0.51486 
Calf ns ns ns ns ns ns ns 
BMI -0.3933 -0.3949 -0.3002 -0.4105 ns ns 0.3801 
Fasting insulin -0.3745 -0.375 -0.3297 -0.4069 ns ns 0.3556 
HOMA-IR -0.3768 -0.377 -0.3289 -0.4137 ns ns 0.3514 
QUICKI 0.4057 0.4224 0.3909 0.4509 ns ns -0.4272 
Fasting glucose ns ns ns ns ns ns ns 
2-h glucose ns ns ns ns ns -0.3092 ns 
Fasting triglycerides -0.3984 -0.4513 -0.4579 -0.4907 ns ns 0.4923 
 
Table 4: Spearman correlation coefficient (rs) for significant correlations between adiponectin fractions and 
variables listed (p < 0.05). BMI, body mass index; HMW, MMW and LMW, high, medium and low molecular 
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Manuscript Figure 1: Box and whisker plots showing distribution of (a)total adiponectin, (b)HMW adiponectin, 
(c)HMW: total adiponectin ratio and (d)LMW: total adiponectin ratio among the three groups. HMW, high 
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Manuscript Figure 2: Distribution of HMW: total adiponectin ratio in patients with (a) HOMA-IR ≤ or > 1.95 
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C.11. SUPPLEMENTAL DATA 
Anthropometry 
All measurements were performed with the participants standing, in duplicate, by trained 
examiners, and the mean used. Examiners were trained on proper performance of the 
various measurements. Measurements were cross-validated on a number of subjects until 
variability between duplicate measurements was low. Body weight was measured on a 
calibrated balance, with the participants wearing minimal clothing or an examination 
gown. A calibrated wall-mounted stadiometer was used to measure height. Body 
circumferences (waist and hip) were measured using measuring tape, as follows: waist 
circumference was measured at the highest point of the iliac crest, while the hip 
circumference was measured at the level of the greatest gluteal protuberance. Skin fold 
thickness at the calf was measured using calibrated skinfold calipers, medially at the level 
of largest circumference. 
PI patients 
Two of the 22 patients were subsequently discovered to have stopped PI therapy 2 and 
2.5 months prior to recruitment to this study. Patient 1 had been receiving Atazanavir for 
30 months before her PI was stopped. Patient 2 had been receiving LPV/r for 6 months. 
Her PI was stopped 2.5 months prior to recruitment. Despite being on Atazanavir, the 
HMW: total adiponectin ratio in this patient was 0.30 (lower than the median ratio for the 
PI group) while the ratio in Patient 2 was 0.35 (the median ratio in the PI group). Their 
data were therefore included in the analyses. 
Medium molecular weight adiponectin 
Using the multimeric adiponectin assay, we also assessed medium and low molecular 
weight (MMW and LMW, respectively) adiponectin. Supplemental Data Table 1 shows 
median (inter-quartile range (IQR)) for the MMW adiponectin form and its ratio to total 
adiponectin. It is evident that the MMW weight adiponectin is significantly lower in the 
PI and non-PI groups when compared to the TN group. However, as is the case with total 
and HMW adiponectin, there is not a statistical difference between the PI and non-PI 
groups (Supplemental Data Table 3). The MMW ratio to total adiponectin did not differ 
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MMW adiponectin 1.27 1.53 1.87 p = 0.0688 
 0.88 - 2.29 0.71 – 1.97 1.55 – 2.85  
MMW: total adiponectin 0.26 0.23 0.24 p = 0.1156 
 0.21 – 0.34 0.16 – 0.27 0.17 – 0.29  
Lipodystrophy score  -  atrophy 2 0 0 p= 0.0479 
 0 - 7 0 -0 0 - 6  
Lipodystrophy score  -  hypertrophy 1 0 0 p = 0. 311 
 0-3 0-3 0-1  
Lipodystrophy score  -  total 4 0 2 p = 0.1485 
 0 - 10 0 – 5 0 – 7  
 
Supplemental Data Table 1:  MMW (in ug/ml), its ratio to total adiponectin  and the lipodystrophy scores: 




Supplemental Data Table 1 lists the median (IQR) scores for the lipodystrophy score and 
its lipoatrophy and -hypertrophy portions for each group. It is evident, as mentioned in 
the manuscript that the differences are not significant for the total score or the 
hypertrophy portion thereof. While the atrophy portion of the score shows a difference 
between the groups, it just barely reaches significance. 
 
The lipodystrophy score comprised eight sites listed in Supplemental Data Table 2. 
Patients were asked to give a score of severity (0 to 3) if lipoatrophy or -hypertrophy was 
experienced in any of the sites. This table shows the number of patients affected in the 
different regions and the median (IQR) scores of severity reported in each region. It is 
evident that more patients in the PI group perceived atrophic changes in the 8 regions 
than did those in the non-PI group. This difference was confirmed using the KW test 
(Supplemental Data Table 1). Non-PI group had fewer patients reporting atrophic 
changes when compared to the TN group. However, no difference was evident between 
the PI and TN groups (Supplemental Data Table 3). Also, more patients in the PI and 
non-PI groups claimed to have experienced hypertrophy in the breasts, abdomen and 
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fat hypertrophy. Lipomata were present in all three groups. As this was a cross-sectional 
cohort study, this data was subjectively obtained from patients at one visit and were not 
compared to objective findings from a clinician. Therefore, the scores and therewith, the 
findings, may be questionable. However, as mentioned in the manuscript, the lack of 
obvious difference among the groups was confirmed by no difference in waist 
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 PI Group non-PI Group TN Group 
  n (%) median (IQR) n (%) median (IQR) n (%) median 
(IQR) 
Lipoatrophy       
Face 5 (23) 2 (1 - 3) 2 (9) 2 (1 - 2) 4 (18) 3 (2 - 3) 
Neck 5 (23) 2 (1 - 2) 0 (0) 0 (0) 5 (23) 2 (2 - 3) 
Dorso-cervical spine 4 (18) 2  0 (0) 0 (0) 5 (23) 2 (2 - 3) 
Arms 5 (23) 3 (2 - 3) 1 (5) 3  8 (36) 2 (1 - 2) 
Breasts  2 (9) 3 (2 - 3) 0 (0) 0 (0) 4 (18) 2  
Abdomen 5 (23) 2 (1 - 3) 1 (5) 3  5 (23) 3 (2 - 3) 
Buttocks 10 (45) 3 (2 - 3) 1 (5) 2  7 (32) 2 (2 - 3) 
Legs 8 (36) 3 (2 - 3) 2 (9) 2 (1 - 2) 7 (32) 2 (2 -3) 
        
Fat accumulation       
Face 3 (14) 3  2 (9) 2 (2 - 3) 1 (5) 2  
Neck 0 (0) 0 (0) 2 (9) 2 (2 - 3) 1 (5) 3  
Dorso-cervical spine 0 (0) 0 (0) 2 (9) 2 (2 - 3) 0 (0) 0  
Arms 2 (9) 2 (1 - 2) 3 (14) 1 (1 - 2) 1 (5) 2  
Breasts  6 (27) 3 (2 - 3) 5 (23) 1 (1 - 2) 0 (0) 0  
Abdomen 5 (23) 2 (1 - 2) 3 (14) 1  2 (9) 1  
Buttocks 2 (9) 2 (1 - 2) 3 (14) 1 (1 - 2) 1 (5) 1  
Legs 0 (0) 0 (0) 2 (9) 1  1 (5) 1  
Lipomata 4 (18) 2 (1 - 3) 2 (9) 2 (2 - 3) 5 (23) 2  
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Supplemental Data Table 3 lists the variables that significantly different among the 
groups. Reference has been made to these analytes in the manuscript.  
 
 PI vs non-PI PI vs TN non-PI vs TN 
Total adiponectin 0.6985 0.0299 0.0290 
HMW adiponectin 0.1927 0.0005 0.0183 
HMW: total adiponectin 0.0019 0.0000 0.0167 
MMW adiponectin 0.8973 0.0845 0.0250 
MMW: total adiponectin 0.0620 0.1392 0.3916 
LMW adiponectin 0.7160 0.4455 0.7513 
LMW: total adiponectin 0.0803 0.0004 0.0095 
f- cholesterol 0.7513 0.0072 0.0020 
f- triglycerides 0.5652 0.0037 0.0133 
HDL 0.2649 0.0620 0.0290 
LDL 0.3185 0.1242 0.0050 
Lipodystrophy score - atrophy 0.0265 0.5732 0.1887 
CD 4 count  0.0416 0.0001 0.0078 
 
Supplemental Data Table 3: Mann-Whitney U derived p-values for differences between the various groups. p 
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Correlations  
Supplemental Data Table 4 lists the correlation coefficients between the various 
variables, as determined by Spearman correlation test. The findings for most variables 
were discussed in the manuscript. Interestingly, as with total and HMW adiponectin, the 
MMW adiponectin form correlated positively with QUICKI and negatively with HOMA-
IR, fasting cholesterol and fasting triglyceride levels. Furthermore, it correlated 
positively with total and HMW adiponectin and the HMW: total adiponectin ratio.  
 






age 1.000 -0.077 0.231 0.140 -0.030 0.021 -0.016 -0.045 -0.135 -0.030 -0.005 0.078 0.132 
bmi -0.077 1.000 0.029 0.834 0.431 0.146 -0.393 -0.395 -0.300 -0.410 -0.071 -0.170 0.380 
whr 0.231 0.029 1.000 0.389 -0.216 0.202 -0.414 -0.425 -0.397 -0.387 0.089 -0.281 0.308 
waist 0.140 0.834 0.389 1.000 0.315 0.325 -0.535 -0.552 -0.484 -0.506 -0.018 -0.176 0.515 
calf -0.030 0.431 -0.216 0.315 1.000 0.031 0.048 0.043 0.060 0.094 0.099 0.010 -0.036 
CD4 0.021 0.146 0.202 0.325 0.031 1.000 -0.428 -0.494 -0.543 -0.298 0.103 -0.099 0.471 
TA -0.016 -0.393 -0.414 -0.535 0.048 -0.428 1.000 0.958 0.726 0.813 -0.082 0.530 -0.695 
HMW -0.045 -0.395 -0.425 -0.552 0.043 -0.494 0.958 1.000 0.870 0.771 -0.135 0.425 -0.784 
HMW: TA -0.135 -0.300 -0.397 -0.484 0.060 -0.543 0.726 0.870 1.000 0.578 -0.253 0.152 -0.826 
MMW -0.030 -0.410 -0.387 -0.506 0.094 -0.298 0.813 0.771 0.578 1.000 0.397 0.185 -0.832 
MMW: TA -0.005 -0.071 0.089 -0.018 0.099 0.103 -0.082 -0.135 -0.253 0.397 1.000 -0.495 -0.265 
LMW 0.078 -0.170 -0.281 -0.176 0.010 -0.099 0.530 0.425 0.152 0.185 -0.495 1.000 0.122 
LMW: TA 0.132 0.380 0.308 0.515 -0.036 0.471 -0.695 -0.784 -0.826 -0.832 -0.265 0.122 1.000 
f-Ins -0.030 0.359 0.221 0.418 0.127 0.116 -0.375 -0.375 -0.330 -0.407 0.073 -0.201 0.356 
f-glu 0.220 0.025 0.218 0.146 0.021 0.144 -0.108 -0.094 -0.037 -0.135 -0.073 -0.165 0.034 
2hr glu 0.226 0.117 0.322 0.115 -0.115 0.247 -0.184 -0.190 -0.188 -0.191 -0.037 -0.309 0.160 
HOMA-IR -0.032 0.352 0.236 0.419 0.127 0.136 -0.377 -0.377 -0.329 -0.414 0.066 -0.209 0.351 
QUICKI -0.022 -0.355 -0.288 -0.451 -0.128 -0.133 0.406 0.422 0.391 0.451 -0.019 0.142 -0.427 
f-chol 0.140 0.148 0.072 0.210 -0.207 0.173 -0.004 -0.049 -0.171 -0.098 0.058 0.040 0.121 
f-tg 0.251 0.247 0.359 0.363 -0.118 0.202 -0.398 -0.451 -0.458 -0.491 -0.094 -0.056 0.492 
HDL -0.053 0.097 -0.257 0.046 -0.144 0.099 0.159 0.159 0.080 0.118 0.030 0.075 -0.089 
LDL 0.167 0.080 -0.013 0.109 -0.141 0.069 0.085 0.042 -0.069 0.000 0.045 0.088 0.016 
hdl/ldl -0.220 0.052 -0.270 -0.027 -0.023 0.043 0.014 0.060 0.127 0.080 -0.015 -0.039 -0.100 
LS -0.004 -0.257 0.021 -0.238 -0.301 -0.065 -0.038 -0.060 -0.137 0.098 0.242 -0.065 -0.065 
LS-A 0.052 -0.281 0.124 -0.213 -0.238 0.054 -0.005 -0.049 -0.171 0.146 0.287 -0.037 -0.054 
LS-H -0.068 -0.017 -0.028 -0.017 -0.172 0.010 -0.111 -0.119 -0.100 -0.056 0.073 -0.140 0.008 
 
Supplemental Data Table 4: Spearman correlation coefficients (rs) showing the relationships between the 
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  f-Ins f-glu 2hr glu HOMA-
IR 
QUICKI f-chol f-tg HDL LDL hdl/ldl LS LS-A LS-H 
age -0.030 0.220 0.226 -0.032 -0.022 0.140 0.251 -0.053 0.167 -0.220 -0.004 0.052 -0.068 
bmi 0.359 0.025 0.117 0.352 -0.355 0.148 0.247 0.097 0.080 0.052 -0.257 -0.281 -0.017 
whr 0.221 0.218 0.322 0.236 -0.288 0.072 0.359 -0.257 -0.013 -0.270 0.021 0.124 -0.028 
waist 0.418 0.146 0.115 0.419 -0.451 0.210 0.363 0.046 0.109 -0.027 -0.238 -0.213 -0.017 
calf 0.127 0.021 -0.115 0.127 -0.128 -0.207 -0.118 -0.144 -0.141 -0.023 -0.301 -0.238 -0.172 
CD4 0.116 0.144 0.247 0.136 -0.133 0.173 0.202 0.099 0.069 0.043 -0.065 0.054 0.010 
TA -0.375 -0.108 -0.184 -0.377 0.406 -0.004 -0.398 0.159 0.085 0.014 -0.038 -0.005 -0.111 
HMW -0.375 -0.094 -0.190 -0.377 0.422 -0.049 -0.451 0.159 0.042 0.060 -0.060 -0.049 -0.119 
HMW
: TA 
-0.330 -0.037 -0.188 -0.329 0.391 -0.171 -0.458 0.080 -0.069 0.127 -0.137 -0.171 -0.100 
MMW -0.407 -0.135 -0.191 -0.414 0.451 -0.098 -0.491 0.118 0.000 0.080 0.098 0.146 -0.056 
MMW
: TA 
0.073 -0.073 -0.037 0.066 -0.019 0.058 -0.094 0.030 0.045 -0.015 0.242 0.287 0.073 
LMW -0.201 -0.165 -0.309 -0.209 0.142 0.040 -0.056 0.075 0.088 -0.039 -0.065 -0.037 -0.140 
LMW: 
TA 
0.356 0.034 0.160 0.351 -0.427 0.121 0.492 -0.089 0.016 -0.100 -0.065 -0.054 0.008 
f-Ins 1.000 0.192 0.072 0.993 -0.903 0.069 0.188 -0.116 0.051 -0.205 -0.029 -0.065 0.071 
f-glu 0.192 1.000 0.408 0.285 -0.254 0.225 0.093 0.094 0.239 -0.160 -0.158 -0.179 -0.016 
2hr 
glu 
0.072 0.408 1.000 0.099 -0.114 0.124 0.268 -0.021 0.031 -0.038 -0.162 -0.106 -0.024 
HOM
A-IR 
0.993 0.285 0.099 1.000 -0.910 0.102 0.193 -0.085 0.081 -0.203 -0.046 -0.083 0.062 
QUIC
KI 
-0.903 -0.254 -0.114 -0.910 1.000 -0.113 -0.208 0.106 -0.108 0.232 0.099 0.124 -0.022 
f-chol 0.069 0.225 0.124 0.102 -0.113 1.000 0.390 0.658 0.851 -0.071 -0.088 -0.228 0.124 
f-tg 0.188 0.093 0.268 0.193 -0.208 0.390 1.000 0.033 0.134 -0.041 0.003 0.073 0.021 
HDL -0.116 0.094 -0.021 -0.085 0.106 0.658 0.033 1.000 0.417 0.595 -0.097 -0.245 0.158 
LDL 0.051 0.239 0.031 0.081 -0.108 0.851 0.134 0.417 1.000 -0.406 -0.094 -0.246 0.063 
hdl/ldl -0.205 -0.160 -0.038 -0.203 0.232 -0.071 -0.041 0.595 -0.406 1.000 -0.076 -0.075 0.066 
LS -0.029 -0.158 -0.162 -0.046 0.099 -0.088 0.003 -0.097 -0.094 -0.076 1.000 0.826 0.603 
LS-A -0.065 -0.179 -0.106 -0.083 0.124 -0.228 0.073 -0.245 -0.246 -0.075 0.826 1.000 0.172 
LS-H 0.071 -0.016 -0.024 0.062 -0.022 0.124 0.021 0.158 0.063 0.066 0.603 0.172 1.000 
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Supplemental Data Figures 1-8 are visual representations of correlation data for the 
HMW: total adiponectin ratio, already discussed in the manuscript. Notably, the ratio 
correlated negatively with established markers of insulin resistance (including BMI, 
HOMA-IR, WHR and triglycerides), but also with waist (which may be due to BMI 
increase) and positively with a known marker of insulin sensitivity (QUICKI). In 
addition, it also correlated negatively with the CD 4 count. As CD 4 count was highest in 
patients on protease inhibitor therapy, this may be the reason for the correlation.  




























y = 0.7116 - 0.0098*x;  rs = -0.300, p <0.05
 
Supplemental Data Figure 4: The  relationship between HMW: total adiponectin  ratios in serum and BMI. rs is 
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y = 0.8082 - 0.4159*x;  rs = -0.397, p <0.05
 
Supplemental Data Figure 5: Relationship between HMW:  total adiponectin ratios in serum and WHR. rs is the 
Spearman correlation coefficient; p<0.05 deemed statistically significant. 
 
 




























y = 1.0631 - 0.0072*x; rs = -0.484, p <0.05
 
Supplemental Data Figure 6: Relationship between HMW: total adiponectin  ratio and waist measurement. rs is 
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y = 0.4998 - 0.0076*x;  rs = -0.333, p <0.05
 
Supplemental Data Figure 7: Relationship between HMW: total adiponectin and fasting insulin concentration in 
serum. rs is the Spearman correlation coefficient; p<0.05 deemed  statistically significant. 
 




























y = 0.4965 - 0.031*x;  r s = -0.329, p <0.05
 
Supplemental Data Figure 8: Relationship between HMW: total adiponectin ratio and HOMA-IR. rs is the 
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y = 0.2823 + 0.4184*x; rs = 0.391, p<0.05
 
Supplemental Data Figure 9: Relationship between HMW: total adiponectin ratio and QUICKI. rs is the 
Spearman correlation coefficient; p<0.05 deemed statistically significant. 
 




























y = 0.5684 - 0.0902*x; rs = -0.458; p <0.05
 
Supplemental Data Figure 10: Relationship between HMW: total adiponectin ratio and serum triglyceride 
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y = 0.5598 - 0.0004*x;  rs = -0.543, p <0.05
 
Supplemental Data Figure 11: Relationship between CD 4 count and HMW: total adiponectin ratio in    serum. 
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Multivariate analyses 
Multivariate analysis was performed to assess the effect of possible confounders on the 
correlations described previously. The following tables (Supplemental Data Tables 5-13) 
represent these data. The findings have been described and discussed in the manuscript. 
 
 
  Univariable  Multivariable 
Variable   Coefficient 95% CI p-value  Coefficient 95% CI p-value 
TOTAL ADIPONECTIN        
ARV treatment        
 None(ref) 1    1   
 Yes, without PI's -1.7530 (-5.1842,-0.0024) 0.3205  -1.3005 (-4.4220,1.8211) 0.4174 
 Yes, with PI's -2.3200 (-5.7512,-0.5693) 0.1899  -1.0230 (-4.2154,2.1694) 0.5323 
         
BMI (per unit increase) -0.4485 (-0.7145,-0.3127) 0.0016*  0.0340 (-0.4507,0.5186) 0.8912 
         
Waist (per unit increase) -0.2657 (-0.3895,-0.2026) 0.0001*  -0.2726 (-0.5114,-0.0339) 0.0289* 
HMW:TOTAL ADIPONECTIN        
ARV treatment        
 None(ref) 1    1   
 Yes, without PI's -0.0825 (-0.1527,-0.0467) 0.0244*  -0.0720 (-0.1336,-0.0105) 0.0253* 
 Yes, with PI's -0.2052 (-0.2754,-0.1694) <0.0001*  -0.1729 (-0.2358,-0.1099) <0.0001* 
         
BMI (per unit increase) -0.0098 (-0.0165,-0.0063) 0.0062*  0.0066 (-0.0030,0.0161) 0.1830 
         
Waist (per unit increase) -0.0072 (-0.0102,-0.0056) <0.0001*  -0.0084 (-0.0131,-0.0037) 0.0008* 
HMW ADIPONECTIN        
ARV treatment        
 None(ref) 1    1   
 Yes, without PI's -1.4482 (-3.5402,-0.3809) 0.1797  -1.1789 (-3.0928,0.7351) 0.2320 
 Yes, with PI's -2.8091 (-4.9010,-1.7418) 0.0107*  -2.0387 (-3.9961,-0.0812) 0.0456* 
         
BMI (per unit increase) -0.2824 (-0.4509,-0.1965) 0.0017*  0.0165 (-0.2807,0.3136) 0.9138 
         
Waist (per unit increase) -0.1704 (-0.2484,-0.1306) 0.0001*  -0.1609 (-0.3073,-0.0145) 0.0352* 
                  
 
Supplemental Data Table 5: : Multivariate analysis adjusting for BMI, showing the correlations between waist 














 Page 84 of 135 
FIERDOZ OMAR OMRFIE001 MMED (CHEM PATH)  
 
  Univariable  Multivariable 
Variable   Coefficient 95% CI p-value  Coefficient 95% CI p-value 
TOTAL ADIPONECTIN        
ARV treatment        
 None(ref) 1    1   
 Yes, without PI's -1.7530 (-5.1842,-0.0024) 0.3205  -1.9878 (-5.1402,1.1646) 0.2212 
 Yes, with PI's -2.3200 (-5.7512,-0.5693) 0.1899  -1.6013 (-4.7402,1.5376) 0.3213 
         
BMI (per unit increase) -0.4485 (-0.7145,-0.3127) 0.0016*  -0.3423 (-0.6155,-0.0691) 0.0169* 
         
Fasting insulin (per unit increase) -0.2795 (-0.4683,-0.1831) 0.0051*  -0.2176 (-0.4104,-0.0249) 0.0307* 
         
HMW:TOTAL ADIPONECTIN         
ARV treatment        
 None(ref) 1    1   
 Yes, without PI's -0.0825 (-0.1527,-0.0467) 0.0244*  -0.0910 (-0.1549,-0.0271) 0.0070* 
 Yes, with PI's -0.2052 (-0.2754,-0.1694) <0.0001*  -0.1913 (-0.2549,-0.1276) <0.0001* 
         
BMI (per unit increase) -0.0098 (-0.0165,-0.0063) 0.0062*  -0.0055 (-0.0110,0.0001) 0.0572 
         
Fasting insulin (per unit increase) -0.0076 (-0.0123,-0.0053) 0.0020*  -0.0058 (-0.0097,-0.0018) 0.0054* 
         
HMW ADIPONECTIN        
ARV treatment        
 None(ref) 1    1   
 Yes, without PI's -1.4482 (-3.5402,-0.3809) 0.1797  -1.5841 (-1.8064,-1.3618) 0.1134 
 Yes, with PI's -2.8091 (-4.9010,-1.7418) 0.0107*  -2.3801 (-2.4160,-2.3441) 0.0183* 
         
BMI (per unit increase) -0.2824 (-0.4509,-0.1965) 0.0017*  -0.2057 (-0.2432,-0.1681) 0.0192* 
         
Fasting insulin (per unit increase) -0.1744 (-0.2941,-0.1133) 0.0058*  -0.1282 (-0.2017,-0.0547) 0.0375* 
                  
 
Supplemental Data Table 6: Multivariate analyses adjusting for BMI showing the correlations between fasting 
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  Univariable  Multivariable 
Variable   Coefficient 95% CI p-value  Coefficient 95% CI p-value 
TOTAL ADIPONECTIN        
ARV treatment        
 None(ref) 1    1   
 Yes, without PI's -1.7530 (-5.1842,-0.0024) 0.3205  -1.9957 (-5.1502,1.1587) 0.2197 
 Yes, with PI's -2.3200 (-5.7512,-0.5693) 0.1899  -1.7071 (-4.8452,1.4311) 0.2905 
         
BMI (per unit increase) -0.4485 (-0.7145,-0.3127) 0.0016*  -0.3455 (-0.6180,-0.0729) 0.0157* 
         
HOMA-IR (per unit increase) -1.1053 (-1.8677,-0.7163) 0.0060*  -0.8682 (-1.6398,-0.0965) 0.0312* 
         
HMW:TOTAL ADIPONECTIN        
ARV treatment        
 None(ref) 1    1   
 Yes, without PI's -0.0825 (-0.1527,-0.0467) 0.0244*  -0.0924 (-0.1556,-0.0293) 0.0057* 
 Yes, with PI's -0.2052 (-0.2754,-0.1694) <0.0001*  -0.1940 (-0.2569,-0.1312) <0.0001* 
         
BMI (per unit increase) -0.0098 (-0.0165,-0.0063) 0.0062*  -0.0054 (-0.0108,0.0001) 0.0589 
         
HOMA-IR (per unit increase) -0.0310 (-0.0497,-0.0215) 0.0018*  -0.0250 (-0.0404,-0.0095) 0.0024* 
         
HMW ADIPONECTIN        
ARV treatment        
 None(ref) 1    1   
 Yes, without PI's -1.4482 (-3.5402,-0.3809) 0.1797  -1.5972 (-3.5274,0.3331) 0.1100 
 Yes, with PI's -2.8091 (-4.9010,-1.7418) 0.0107*  -2.4423 (-4.3626,-0.5220) 0.0154* 
         
BMI (per unit increase) -0.2824 (-0.4509,-0.1965) 0.0017*  -0.2061 (-0.3729,-0.0394) 0.0184* 
         
HOMA-IR (per unit increase) -0.6922 (-1.1753,-0.4457) 0.0066*  -0.5257 (-0.9979,-0.0536) 0.0329* 
                  
 
Supplemental Data Table 7: Multivariate analysis, adjusting for BMI, showing the corrrelations between 
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  Univariable  Multivariable 
Variable   Coefficient 95% CI p-value  Coefficient 95% CI p-value 
TOTAL ADIPONECTIN        
ARV treatment        
 None(ref) 1    1   
 Yes, without PI's -1.7530 (-5.1842,-0.0024) 0.3205  -1.7981 (-5.0211,1.4249) 0.2785 
 Yes, with PI's -2.3200 (-5.7512,-0.5693) 0.1899  -1.5902 (-4.8045,1.6241) 0.3360 
         
BMI (per unit increase) -0.4485 (-0.7145,-0.3127) 0.0016*  -0.3748 (-0.6540,-0.0956) 0.0108* 
         
QUICKI (per unit increase) 12.7802 (1.1205,18.7290) 0.0355*  8.4803 (-3.3898,20.3504) 0.1665 
         
HMW:TOTAL ADIPONECTIN        
ARV treatment        
 None(ref) 1    1   
 Yes, without PI's -0.0825 (-0.1527,-0.0467) 0.0244  -0.0881 (-0.1535,-0.0228) 0.0104 
 Yes, with PI's -0.2052 (-0.2754,-0.1694) <0.0001  -0.1901 (-0.2553,-0.1250) <0.0001 
         
BMI (per unit increase) -0.0098 (-0.0165,-0.0063) 0.0062*  -0.0059 (-0.0116,-0.0003) 0.0436* 
         
QUICKI (per unit increase) 0.4150 (0.1320,0.5593) 0.0055*  0.2817 (0.0411,0.5222) 0.0252* 
         
HMW ADIPONECTIN        
ARV treatment        
 None(ref) 1    1   
 Yes, without PI's -1.4482 (-3.5402,-0.3809) 0.1797  -1.4989 (-3.4629,0.4651) 0.1398 
 Yes, with PI's -2.8091 (-4.9010,-1.7418) 0.0107*  -2.3633 (-4.3219,-0.4046) 0.0212* 
         
BMI (per unit increase) -0.2824 (-0.4509,-0.1965) 0.0017*  -0.2200 (-0.3901,-0.0499) 0.0138* 
         
QUICKI (per unit increase) 8.8494 (1.5237,12.5870) 0.0209*  5.7069 (-1.5263,12.9402) 0.1272 
                  
 
Supplemental Data Table 8: Multivariate analysis, adjusting for BMI, showing the correlations between 
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  Univariable  Multivariable 
Variable   Coefficient 95% CI p-value  Coefficient 95% CI p-value 
HMW:TOTAL ADIPONECTIN        
ARV treatment        
 None(ref) 1    1   
 Yes, without PI's -0.0825 (-0.1527,-0.0467) 0.0244*  -0.0277 (-0.1139,0.0585) 0.5308 
 Yes, with PI's -0.2052 (-0.2754,-0.1694) <0.0001*  -0.0864 (-0.2170,0.0441) 0.1992 
         
CD4 count (per unit increase) -0.0004 (-0.0005,-0.0003) <0.0001*  -0.0002 (-0.0004,-0.0001) 0.0056* 
         
Duration HAART (per unit increase) -0.0060 (-0.0081,-0.0049) <0.0001*  -0.0023 (-0.0061,0.0016) 0.2492 
TOTAL ADIPONECTIN        
ARV treatment        
 None(ref) 1    1   
 Yes, without PI's -1.7530 (-5.1842,-0.0024) 0.3205  -3.1000 (-7.3679,1.1678) 0.1596 
 Yes, with PI's -2.3200 (-5.7512,-0.5693) 0.1899  -4.6426 (-11.1050,1.8199) 0.1642 
         
CD4 count (per unit increase) -0.0091 (-0.0157,-0.0058) 0.0082*  -0.0096 (-0.0171,-0.0021) 0.0149* 
         
Duration HAART (per unit increase) -0.0211 (-0.1249,0.0318) 0.6910  0.1633 (-0.0271,0.3537) 0.0980 
HMW         
ARV treatment        
 None(ref) 1    1   
 Yes, without PI's -1.4482 (-3.5402,-0.3809) 0.1797  -1.9612 (-4.6029,0.6804) 0.1508 
 Yes, with PI's -2.8091 (-4.9010,-1.7418) 0.0107*  -3.6227 (-7.6226,0.3773) 0.0809 
         
CD4 count (per unit increase) -0.0067 (-0.0108,-0.0046) 0.0019*  -0.0055 (-0.0101,-0.0008) 0.0250* 
         
Duration HAART (per unit month 
increase) 
-0.0552 (-0.1195,-0.0223) 0.0978  0.0749 (-0.0429,0.1928) 0.2175 
                  
 
Supplemental Data Table 9: Multivariate analysis, adjusting for duration of HAART, showing the correlation 
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  Univariable  Multivariable 
Variable   Coefficient 95% CI p-value  Coefficient 95% CI p-value 
WAIST         
ARV treatment        
 None(ref) 1    1   
 Yes, without PI's 1.7386 (-4.2359,4.7869) 0.5704  1.3819 (-6.3591,9.1229) 0.7276 
 Yes, with PI's 4.9318 (-1.0427,7.9800) 0.1107  3.7401 (-7.9813,15.4616) 0.5340 
         
CD 4 count (per unit increase) 0.0139 (0.0023,0.0198) 0.0223*  0.0120 (-0.0016,0.0257) 0.0887 
         
Duration HAART  (per unit 
month increase) 
0.1173 (-0.0624,0.2090) 0.2055  -0.0604 (-0.4058,0.2850) 0.7330 
         
 
Supplemental Data Table 10: Multivariate analysis, adjusting for duration of HAART, showing the relationship 













 Page 89 of 135 
FIERDOZ OMAR OMRFIE001 MMED (CHEM PATH)  
 
  Univariate  Multivariate 
Variable   Coefficient 95% CI p-value  Coefficient 95% CI p-value 
MMW ADIPONECTIN        
ARV treatment        
 None(ref) 1    1   
 Yes, without PI's -0.3973 (-1.4546,0.6600) 0.4641  -0.4528 (-1.4413,0.0516) 0.3729 
 Yes, with PI's -0.0458 (-1.1031,1.0116) 0.9327  0.1624 (-0.8219,0.6646) 0.7475 
         
BMI (per unit increase) -0.1254 (-0.2077,-0.0431) 0.0040*  -0.1030 (-0.1886,-0.0592) 0.0217* 
         
Fasting insulin (per unit increase) -0.0723 (-0.1310,-0.0136) 0.0186*  -0.0581 (-0.1186,-0.0273) 0.0642 
         
LMW:TOTAL ADIPONECTIN        
ARV treatment        
 None(ref) 1    1   
 Yes, without PI's 0.0951 (0.0179,0.1722) 0.0186*  0.1026 (0.0326,0.1383) 0.0056* 
 Yes, with PI's 0.1655 (0.0883,0.2426) 0.0001*  0.1491 (-0.0697,0.0355) 0.0001* 
         
BMI (per unit increase) 0.0110 (0.0043,0.0177) 0.0021*  0.0071 (0.0010,0.0102) 0.0249* 
         
Fasting insulin (per unit increase) 0.0075 (0.0028,0.0122) 0.0027*  0.0058 (0.0015,0.0080) 0.0101* 
                  
 
Supplemental Data Table 11: Multivariate analysis adjusting for BMI, showing the correlations between fasting 
insulin concentration and MMW (medium molecular weight) adiponectin and the LMW (low molecular 
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  Univariate  Multivariate 
Variable   Coefficient 95% CI p-value  Coefficient 95% CI p-value 
MMW ADIPONECTIN        
ARV treatment        
 None(ref) 1    1   
 Yes, without PI's -0.3973 (-1.4546,0.6600) 0.4641  -0.4511 (-1.4418,0.0543) 0.3756 
 Yes, with PI's -0.0458 (-1.1031,1.0116) 0.9327  0.1341 (-0.8514,0.6370) 0.7906 
         
BMI (per unit increase) -0.1254 (-0.2077,-0.0431) 0.0040*  -0.1045 (-0.1900,-0.0608) 0.0199* 
         
HOMA-IR (per unit increase) -0.2844 (-0.5212,-0.0475) 0.0217*  -0.2256 (-0.4679,-0.1019) 0.0730 
         
LMW:TOTAL ADIPONECTIN        
ARV treatment        
 None(ref) 1    1   
 Yes, without PI's 0.0951 (0.0179,0.1722) 0.0186*  0.1035 (0.0339,0.1390) 0.0050* 
 Yes, with PI's 0.1655 (0.0883,0.2426) 0.0001*  0.1519 (-0.0692,0.0353) 0.0001* 
         
BMI (per unit increase) 0.0110 (0.0043,0.0177) 0.0021*  0.0071 (0.0011,0.0101) 0.0244* 
         
HOMA-IR (per unit increase) 0.0300 (0.0110,0.0489) 0.0029*  0.0243 (0.0073,0.0330) 0.0068* 
                  
 
Supplemental Data Table 12: Multivariate analysis adjusting for BMI, showing the correlations between 
HOMA-IR and MMW (medium molecular weight) adiponectin and the LMW (low molecular weight): total 
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  Univariate  Multivariate 
Variable   Coefficient 95% CI p-value  Coefficient 95% CI p-value 
MMW ADIPONECTIN        
ARV treatment        
 None(ref) 1    1   
 Yes, without PI's -0.3973 (-1.4546,0.6600) 0.4641  -0.4494 (-1.4368,0.0544) 0.3759 
 Yes, with PI's -0.0458 (-1.1031,1.0116) 0.9327  0.1836 (-0.8011,0.6861) 0.7160 
         
BMI (per unit increase) -0.1254 (-0.2077,-0.0431) 0.0040*  -0.1031 (-0.1887,-0.0595) 0.0213* 
         
QUICKI (per unit increase) 4.3327 (0.8050,7.8604) 0.0190*  3.5268 (-0.1100,5.3822) 0.0621 
         
LMW:TOTAL ADIPONECTIN        
ARV treatment        
 None(ref) 1    1   
 Yes, without PI's 0.0951 (0.0179,0.1722) 0.0186*  0.1044 (0.0361,0.1393) 0.0040* 
 Yes, with PI's 0.1655 (0.0883,0.2426) 0.0001*  0.1462 (-0.0682,0.0348) 0.0001* 
         
BMI (per unit increase) 0.0110 (0.0043,0.0177) 0.0021*  0.0067 (0.0008,0.0098) 0.0296* 
         
QUICKI (per unit increase) -0.5124 (-0.7880,-0.2368) 0.0005*  -0.4105 (-0.6623,-0.2821) 0.0022* 
                  
 
Supplemental Data Table 13: Multivariate analysis adjusting for BMI, showing the correlations between 
QUICKI and MMW (medium molecular weight) adiponectin and the LMW (low molecular weight): total 
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D. SUPPORTING DOCUMENTS 
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D.2. COVER LETTER AND ETHICS APPROVAL FOR AMENDMENT 
OF RESEARCH PROTOCOL 
Chemical Pathology 
C20 




Tel: 404 4135 
Fierdoz.omar@uct.ac.za 





Research Ethics Committee 
Health Sciences Faculty 
 
Dear Sir/Madame  
 
PROJECT TITLE: ROLE OF HIGH MOLECULAR WEIGHT MULTIMERIC 
ADIPONECTIN IN THE DEVELOPMENT OF HIV LIPODYSTROPHY SYNDROME 
FOLLOWING ANTI-RETROVIRAL THERAPY 
Last year ethics approval was granted for the above-mentioned research project.  
Due to the fact that there are too few HIV patients on anti retroviral therapy that have already 
been diagnosed with lipodystrophy receiving treatment at the ARV clinic at Groote Schuur 
Hospital, we have decided to alter our subject and control groups slightly to the following 4 
groups:  
Test group: 
1. 30 known HIV positive adult patients on Protease inhibitor anti retroviral treatment for 6 
months and longer. 
Control groups: 
2. 30 known HIV positive adult patients on non-protease inhibitor anti retroviral treatment 
for 6 months and longer. 
3. 30 known HIV positive adult patients, anti retroviral treatment naïve. 
4. 30 known HIV negative healthy subjects. 
 
Also, we have been advised by Prof Gary Maartens to collaborate with Dr Joel Dave’s research 
group as they are also looking into lipodystrophy in the above-mentioned groups, and are 
obtaining the same data that we were looking to obtain (apart from adiponectin levels). We will 
now be obtaining this data as well as blood samples from stored samples obtained by them from 
the above-mentioned subject / control groups. This blood will be used for measurement of the 
different adiponectin levels by Elisa as well as by Western blot. Attached, please find their 
consent form and patient information sheet.  
 





Dr Fierdoz Omar 
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D.3. PATIENT CONSENT FORM (FROM DR JOEL DAVE’S STUDY) 
Written informed consent for patient 
Study number : _______________________ 
Patient initials : _______________________ 
I, ___________________________________________________________________ 
(Name of patient in block letters) 
have read and understood all the information given to me about my participation in this 
study and I have been given the opportunity to discuss it and ask questions. I voluntarily 
agree to take part in this study and have received an information sheet outlining the 
details of this study. I understand that I am able to withdraw from this study at anytime. 
 
__________________                                    ______________ 
Signature of patient        Date 
 
__________________   
Printed name of patient 
 
I have explained the nature and purpose of this study to the patient named above. 
 
__________________ 
Signature of doctor 
 
__________________ 
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D.4. PATIENT INFORMATION SHEET (FROM DR JOEL DAVE’S 
STUDY)  
Patient information sheet for the HAART Study 
You are invited to participate in a research project. 
Before you agree to take part you need to understand the following: 
Many HIV-positive patients around the world are treated with special medications collectively 
called highly active antiretroviral therapy (HAART). Although HAART cannot cure HIV/AIDS it 
has helped to fight the human immunodeficiency virus and has helped patients feel a lot better. 
However, HAART also has side-effects. Some of these side-effects have included the 
development of diabetes, cholesterol problems and changes in body shape (usually either 
increased or decreased fat in certain areas of the body). Very little is known about these problems 
in the HIV-positive patients in South Africa. We therefore want to monitor the effects of HAART 
in patients in Cape Town. This would help the doctors and patients to understand the side-effects 
of HAART, how commonly they occur and how they can best be treated. 
WHAT WILL HAPPEN IF I AGREE TO PARTICIPATE? 
We will ask you not to eat or drink anything from 10 pm the night before your appointment 
however you must take your morning doses of antiretroviral drugs with a full glass of water. At 
your appointment you will be required to complete a questionnaire and give some basic medical 
information about yourself. Following this the doctor will examine you and will then insert a drip 
cannula (a small plastic device that stays inside the vein allowing all further blood samples to be 
taken from it thus avoiding any further need for needle pricks). Using a syringe a sample of blood 
(~ 25 ml, 1 tablespoon) will be taken from the cannula. After taking the blood sample, you will 
be asked to drink a glass of water with glucose, a form of sugar. Further blood samples will be 
taken 30 min and 120 min after completing this drink. The blood will be sent to a laboratory and 
tested for glucose, insulin, cholesterol, lactate and levels of the antiretroviral drugs. Some of the 
blood will be frozen and kept for testing at a later stage. Whilst waiting 
for your blood samples to be taken the study staff will do the following: a) using a tape measure 
they will measure certain areas of your body including your waist, your hips, your height, your 
upper arm and your thigh b) take blood pressure measurements c) measure your body weight 
using a scale. At another appointment special X-rays will be organised, called DEXA and CT 
scans. These scans are done to examine the amount of fat in various areas of your body. All 
transport to and from the X-rays will be provided. Each test takes less than 30 minutes to 
complete. All transport expenses will be re-imbursed and participation in the study will cost you 
nothing. The study staff will also review all previous clinic records including all previous blood 
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WHAT ARE THE POSSIBLE DISCOMFORTS OF PARTICIPATING IN THE STUDY? 
Having blood taken will be the only discomfort in this study. Risk of infection will be minimized 
by using sterile procedures, and all blood samples will be taken by suitably qualified persons.  
WHAT ARE THE POSSIBLE BENEFITS? 
If you are found to have any of the above-mentioned side-effects of HAART then arrangements 
will be made for you to be seen at a hospital where doctors specially trained in looking after these 
problems will look after you. This study will help doctors find these problems early therefore the 
required investigation and treatment can be done before any further problems arise. 
DO I HAVE TO PARTICIPATE? 
You do not have to participate in this study. Your participation is voluntary and if you agree to 
participate then you will be required to sign a form. You can withdraw from the study at anytime 
and this will in no way affect your treatment in the future. 
WILL THE INFORMATION REMAIN CONFIDENTIAL? 
Your records will only be viewed by your doctors and people involved in this study. Your details 
will not be made available to anybody not involved in this study. Although absolute 
confidentiality cannot be guaranteed the staff involved in this study will strive to keep your 
records as confidential as possible. 
CONTACT DETAILS OF STUDY STAFF 
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D.5. PROCEDURE FOR MULTIMERIC ADIPONECTIN ANALYSIS 
(FROM PACKAGE INSERT) 
ALPCO
TM
 Adiponectin (Multimeric) EIA 
For the quanitative, selective determination of High Molecular Weight (HMW), Mid- 
Molecular Weight (MMW) and Total Adiponectin in human serum or plasma. 
 
For Research Use Only. Not For Use In Diagnostic Procedures. 
Catalog Number: 47-ADPH-9755 
Size: 96 Wells 
Storage: 2-10°C 
Version: 03/15/06 – ALPCO04/19/06 
APPLICATION 
This assay is intended for the quantitative, selective determination of High Molecular Weight 
(HMW), Mid-Molecular Weight (MMW) and Total Adiponectin in human serum or plasma. 
INTRODUCTION 
Adiponectin is a 244 amino acid protein (one of several known adipocytokines) secreted by the 
adipocyte. It has been reported that adiponectin circulates in the blood in various oligomeric 
complexes consisting of multiple proteins bound together. These complexes range from dimeric 
forms to a “bouquet” structure of 9 or more proteins. 1-3 Adiponectin has been reported to have 
several physiological actions, such as protective activities against atherosclerosis, improvement 
of insulin sensitivity, and prevention of hepatic fibrosis. In recent years, the relationship of these 
physiological actions with the circulating multimer structure of adiponectin has been attracting 
wide attention. It has been reported recently that the ratio of high-molecular weight adiponectin 
in circulation to total adiponectin level of the subject reflects the condition of disease more 
clearly than total adiponectin levels alone.4-6 The structure of adiponectin multimers was 
elucidated recently by selectively separating each adiponectin multimer from human plasma. This 
led to the discovery of an albumin-binding trimer, in addition to the already documented trimer, 
hexamer and HMW forms. Following a further report that part of the multimer form is able to be 
digested selectively by a certain protease, this kit utilizes a method of measurement incorporating 
pretreatment with proteases for selective measurement of human multimeric adiponectin.7 In 
addition, in order to provide a reference for total adiponectin levels, a new, simple pretreatment 
method is utilized. By using this method, multimeric  adiponectin in the serum is converted 
mainly to a dimer via the addition of an SDS-containing acid buffer (without boiling step). 8 
ASSAY PRINCIPLES 
This kit operates on the principle of a “sandwich” format enzyme-linked immunosorbent assay 
(ELISA). The specific antibodies used in the kit are anti-human adiponectin monoclonal 
antibodies (MoAbs) directed to two independent epitopes. The specimens are pre-treated as 
described below, and total adiponectin and individual multimers of adiponectin are determined 
selectively, directly or indirectly. Multimers of adiponectin are classified into four fractions 
with this kit: 
1) Total adiponectin fraction: “Total-Ad”-assayed directly on the plate 
2) High-molecular adiponectin fraction (equivalent of dodecamer -octodecamer): “HMW-Ad”-
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3) Middle-molecular adiponectin fraction (equivalent of hexamer): “MMW-Ad”-inferred value 
obtained by subtracting the concentration of HMW-Ad from the combined concentration of 
MMW-Ad + HMW-Ad 
4) Low-molecular adiponectin fraction (equivalent of trimer including albumin-binding 
adiponectin): “LMWAd”- inferred value obtained by subtracting the combined concentration of 
MMW-Ad + HMW-Ad from the total concentration of Ad. 
The microtiter plate wells have been coated with an anti-human adiponectin monoclonal 
antibody. Adiponectin in the standards and pretreated specimens are captured by the antibody 
during the first incubation. Afterwards, a wash step removes all unbound material. Subsequently, 
an anti-human adiponectin antibody that has been biotin-labeled is added and binds to the 
immobilized adiponectin in the wells. After the second incubation and subsequent wash step, 
HRP–labeled streptavidin is added. After the third incubation and subsequent wash step, substrate 
solution is added. 
Finally, stop reagent is added after allowing the color to develop. The intensity of the color 
development is read by a microplate reader. The absorbance value reported by the plate reader is 
proportional to the concentration of adiponectin in the sample. 
In this kit, pre-treated normal human serum by sample pre-treatment buffer is used as the 
Calibrator. The sample Pre- Treatment procedure used in this assay is very important for good 
results. It is outlined here briefly, and explained further in the Assay Procedure section of this 
insert. 
 
1) “Total-Ad” assay: Specimens are treated with SDS-containing acid buffer to convert 
multimeric adiponectin mainly to a dimer form. 
2) For “HMW-Ad” assay: The protease that selectively digests LMW-Ad and MMW-Ad acts on 
specimens, and remaining MW-Ad fraction is treated with SDS-containing acid buffer to convert 
it to a dimer form. Upon addition of the SDS-buffer, the digestive reaction of protease is stopped. 
3) For combined “MMW-Ad” and “HMW-Ad” assay: The protease that selectively digests only 
LMW-Ad acts on specimens, and remaining MMW-Ad and HMW-Ad are treated with SDS -
containing acid buffer to convert these fractions to a dimer form. Upon addition of the SDS-
buffer, the digestive reaction of protease is stopped. 
KIT COMPONENTS 
Reagent Composition Amount Part Number 
Wash buffer concentrate Phosphate buffer (pH 7.2) 100 ml x 1 vial 975513-001 
Sample pre-treatment buffer 
Citrate buffer (pH 3.0) containing SDS 50 ml x 1 vial 975520-001 
Dilution buffer Phosphate buffer (pH 7.2) containing BSA 100 ml x 1 vial 975537-001 
Monoclonal Ab coated plate 
Anti-human Adiponectin mouse monoclonal Ab coated 96-well 1 plate 975544-001 
Calibrator Human serum stablized in sample pre-treatment buffer 0.25 ml x 1 vial 
975551-001 
Biotin Labeled MoAb Biotin Conjugated anti-human adiponectin 6.0 mL x 1 vial 975568-
001 
Enzyme-labeled streptavidin 
Horse-radish peroxidase (HRP)- labeled streptavidin 6.0 ml x 1 vial 975575-001 
Substrate (lyophilized) O-phenylenediamine 2 vials 975582-001 
Substrate buffer Citrate buffer (pH 5.0) containing H2O2 15 ml x 1 vial 975599-001 
Stop reagent 7.7% H2SO4 15 ml x 1 vial 975605-001 
Protease I (lyophilized) Protease 1 vial 975612-001 
Protease II (lyophilized) Protease 1 vial 975629-001 
Protease buffer Tris buffer (pH 8.0) 50 ml x 1 vial 975636-001 
REAGENT PREPARATION AND STORAGE 
All reagents must be allowed to reach room temperature prior to use. 
a) Wash buffer 
Dilute Wash buffer concentrate with 900mLof purified water. Working Wash buffer should be 
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b) Sample pre-treatment buffer 
A white precipitate may form in this vial. This precipitate will be completely dissolved by 
warming the solution to room temperature and thoroughly stirring it before use. 
c) Dilution buffer 
Dilution buffer is supplied ready-to-use. 
d) Monoclonal-antibody coated wells 
MoAb coated wells are supplied ready-to-use. The unused strips should be returned to the 
laminate bag and stored at 2-10°C. 
e) Working Calibrator 
Note: There may be a precipitate in the tube. Allow the solution to stand at room temperature and 
stir thoroughly before using. Avoid foaming. 
Just prior to use, dilute the Calibrator 1:101 with Dilution buffer and further the serial dilution to 
create a standard curve: 
**Standard number 1 is the Stock calibration material included with the kit, diluted 
1:101. Actual concentration (diluted 1:101) is found on the vial label; subsequent 




Calibration material to 
add: 
Diluent to add: 
 
1 150 µl of stock solution 0 µl 
2 150 µl of standard 1 150 µl 
3 150 µl of standard 2  150 µl 
4 150 µl of standard 3 150 µl 
5 150 µl of standard 4 150 µl 
6 150 µl of standard 5 150 µl 
7 150 µl of standard 6  150 µl 
8 0 150 µl 
 
* The remaining Calibrator should be stored at 2-10°C and the same procedure should be 
repeated when it is to be used again. 
* Since precipitation is temporarily caused when Calibrator is added to Dilution buffer, stir it 
thoroughly. 
* The working calibrator should be prepared at the same time as the specimen treatment and 
dilution. Add the treated specimen and the working calibrator to the MoAb coated wells in 
succession. 
f) Biotin labeled-MoAb 
Biotin labeled-MoAb is supplied ready-to-use. 
g) Enzyme labeled streptavidin 
Enzyme labeled streptavidin solution is supplied ready-to-use. 
h) Substrate solution 
Just prior to use, reconstitute the Substrate (lyophilized) by adding 6 mL of substrate buffer to the 
substrate vial. The substrate solution should be used immediately after reconstitution and the 
remaining solution should be discarded. 
i) Stop reagent 
Stop reagent is ready-to-use. 
j) Protease solution I 
Reconstitute Protease I (lyophilized) by adding 10 mL of protease buffer to the vial and dissolve 
completely by mixing at room temperature for 15-30min. Protease I is stable for 2 days at 2-
10°C. Freeze below -30°C for extended storage. 
k) Protease solution II 
Reconstitute Protease II (lyophilized) by adding 10 mL of protease buffer to the vial and dissolve 
completely by mixing at room temperature for 15-30 min. Protease II is stable for 2 days at 2-
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1) Pretreatment of specimens 
Each specimen may be treated by any combination of the pretreatment options below, but separate 
aliquots must be used for each option. For example, if HMW and total adiponectin concentrations are 
being quantified on the same sample, treat two aliquots of the sample: one by the “total-Ad” 
procedure and one by the “HMW-Ad” procedure. ●Pre-treatment option 1: For “Total-Ad” assay 
Add 100 µl of Protease Buffer (Tris buffer, pH 8.0) and 400 µL of Sample Pre-treatment Buffer 
to 10 µL of serum or plasma. Stir thoroughly (sample dilution = 1:51). ●Pre-treatment option 2: For combined “MMW-Ad” and “HMW-Ad” assay 
Add 100 µL of Protease Solution I to 10 µL of serum or plasma and incubate for 20 min at 37°C. 
Immediately add 400 µL of Sample Pre-Treatment Buffer. Stir thoroughly (sample dilution = 
1:51). ●Pre-treatment option 3: For “HMW-Ad” assay 
Add 100 µL of the Protease Solution II to 10 µL of serum or plasma and incubate for 20 min at 
37°C. Immediately add 400 µL of the Sample Pre-Treatment Buffer. Stir thoroughly (sample 
dilution = 1:51). 
2) Dilution of Pretreated specimens 
Further dilute pre-treated specimens 1:101 as follows:  
Add 10 µL of the pre-treated specimen obtained in Steps 1 to 3 (see “Pretreatment of 
Specimens”) to 1.0 ml Dilution Buffer (Phosphate Buffer + BSA, pH 7.2). FINAL Sample 
dilution = 1:5151. 
* Since precipitation is temporarily caused when a pretreated specimen is added to Dilution 
buffer, stir thoroughly. 
3) Assay Method 
1) Plan your plate configuration. Determine how many strips will be needed and remove the 
excess strips from the microtiter plate. Store the remaining strips in the laminate bag. 
2) Add 50 µL each of the working calibrator and diluted samples to the appropriate wells, 
according to the plate configuration. 
3) Cover the plate with a plate sealer and incubate for 1 hour at room temperature (20-30 °C). 
4) Decant the plate and strike the plate against absorbent towels to remove any excess liquid. Do 
not introduce absorbent materials into the wells! Wash by adding 350-400 µL of Wash Buffer to 
each well (using a laboratory squeeze bottle, wash manifold, or automated plate washer); decant 
wash buffer and strike plate against absorbent towels to remove residual liquid. Repeat this cycle 
twice, for a total of 3 washes. 
5) Add 50 µL of Biotin-labeled monoclonal antibodies to each well. Cover the plate with a plate 
sealer and incubate for 1 hour at room temperature (20-30 °C). 
6) Repeat wash step as described in Step 4. 
7) Add 50 µL of the Enzyme-labeled streptavidin to each well. Cover the plate with a plate sealer 
and incubate for 30 min at room temperature (20-30 °C). 
8) Repeat wash step as described in Step 4. 
9) Add 50 µL of the Substrate solution to each well. Protect the plate from light and incubate for 
10 min at room temperature (20-30 °C). 
10) Add 50 µL of the Stop solution to each well. 
11) Using a microtiter plate reader set to 492 nm, read the absorbance of each well. Use a 
reference wavelength of 600-700 nm if desired. 
4) Calculations 
Calculate the ∆ absorbance by subtracting the absorbance of the 0 ng/mL calibrator from those of 
other calibrators and diluted samples. Plot the ∆ absorbance of calibrators against the calibrator 
concentration on log-log or semi-log graph paper. Draw a smooth curve through these points to 
construct the calibration curve. Read the concentrations for the Diluted samples from the 
calibration curve. Calculate the concentration for the Diluted samples by multiplying by dilution 
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• “Total-Ad”: Concentration of the specimen prepared by Pre-treatment option 1. 
• “HMW-Ad”: Concentration of the specimen prepared by Pre-treatment option 3. 
“MMW-Ad”: Concentration of the specimen prepared by Pre-treatment option 2 (HMW + MMW 
Ad) minus the concentration of the specimen prepared by Pre-treatment option 3 (HMW-Ad) 
• “LMW-Ad”: Concentration of the specimen prepared by Pre-treatment option 1 (Total-Ad) 




1. This kit has been validated for analyzing human serum, EDTA-plasma or heparinized plasma. 
Citrated plasma must not be used due to unqualified lower results. 
2. Measurements of different adiponectin species of the same serum or plasma samples MUST be 
in the same plate. DO NOT calculate results between different plates. 
3. A calibration curve must be run with each assay. Calibrators and samples should be assayed in 
duplicate. 
4. If the concentration of adiponectin in a specimen exceeds the highest point of the calibration 
curve range, dilute pretreated specimen further with Dilution Buffer and re-assay. 
5. Observe all specified reaction times and temperatures outlined in this manual. These 
parameters are especially important while pre-treating samples with proteases. 
6. If the kit is not used entirely during the premier run, the remaining reagents may be stored as 
directed in the package insert and used one subsequent time before the expiration date. 
7. Samples must be run promptly after the addition of the Sample pre-treatment buffer and added 
to the MoAb coated wells. 
8. Remove all residual liquid completely after each step of the wash procedure. 
9. Do not allow the wells to dry out or be damaged during the washing procedure. 
10. Avoid carrying out this procedure in direct sunlight. 
WARNINGS AND PRECAUTIONS 
1. The human serum contained in the calibrator was tested and found negative for presence of the 
HBs antigen, HIV antibody, and HCV antibody, however all specimens should be handled 
carefully as though capable of transmitting infection. 
2. Stop reagent (7.7% H2SO4) is hazardous and can cause severe burns. In case of eye contact, 
rinse immediately with plenty of water, and seek medical advice. In case of contact with skin or 
clothing, rinse immediately with plenty of water. 
STORAGE OF REAGENTS 
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D.6. OUTCOMES ACHIEVED 
Findings or parts thereof were presented at the following: 
1. American Association for Clinical Chemistry Annual Meeting and Lab Expo, 
July 2009; Chicago USA – POSTER PRESENTATION* (Abstract B) 
2. University of Cape Town School of Biomedical Sciences 3rd Research Day – 
POSTER PRESENTATION, September 2008; POSTER 
PRESENTATION** (Abstract A) 
3. Congress of the Federation for South Societies of Pathology – Update 48, 
July 2008; Cape Town, South Africa – ORAL PRESENTATION*** 
(Abstract A) 
Abstracts included below. 
*Travel award won for presentation of this work. 
**Best poster award won 
***Awarded the Beckman Coulter Postgraduate Bursary Award won for this work. 
ABSTRACT A 
Antiretroviral protease inhibitors decrease high molecular weight / total adiponectin 
ratios in HIV positive patients 
Omar F1, Dave JA2, King JA1, Levitt NS2, Pillay TS1 
1Division Chemical Pathology, UCT, NHLS & Groote Schuur Hospital, 2Division 
Endocrinology, Department of Medicine, UCT 
Introduction: Antiretroviral therapy in HIV patients (especially protease inhibitors (PIs)) 
is associated with the lipodystrophy syndrome, with low total adiponectin (TA) levels 
reported. The high molecular weight (HMW):TA ratio is a better marker of insulin 
resistance.  Aim: To establish whether HMW:TA ratios were lower in HIV positive 
patients receiving PIs compared with those not on PIs. Methodology: 66 HIV positive 
Xhosa female patients were recruited: 22 on PIs for at least 6 months, 22 on non-PIs 
(NPIs) for the same period, and 22 treatment naïve (TN). The NPI and TN groups were 
BMI- and age-matched to the PI group. Adiponectin levels (TA, HMW, medium 
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samples using the Alpco Adiponectin (Multimeric) enzyme immunoassay. Data were 
non-parametrically analysed. Results: The PI and NPI groups had significantly lower 
HMW adiponectin levels than the TN group (median 2.23 and 3.49 vs 5.29mg/l; 
p<0.005). Furthermore, the TA was statistically lower in HIV patients in both treatment 
groups compared with the TN group (p<0.05). HMW:TA ratios were significantly lower 
in the PI group than in both the NPI (p<0.05) and TN (p<0.0001) groups. Conclusion: 
Low HMW:TA ratios in HIV positive patients on PIs may be associated with the 
development of lipodystrophy in these patients. 
 
ABSTRACT B 
High molecular weight / total adiponectin ratios are decreased in HIV-infected women 
receiving protease inhibitors 
Omar F1, Dave JA2, King JA1, Levitt NS2, Pillay TS1 
1Division of Chemical Pathology, University of Cape Town, National Health Laboratory 
Service (NHLS) & Groote Schuur Hospital, 2Division of Endocrinology, University of 
Cape Town 
Relevance: We use two Highly Active Anti-Retroviral Therapy (HAART) regimens for 
the treatment of HIV. Regimen 1 contains 2 nucleotide reverse transcriptase inhibitors 
(NRTIs) (stavudine and lamivudine) and a non-NRTI (efavirenz), while regimen 2 
contains a protease inhibitor (PI) (liponavir/ritonavir) and 2 NRTIs (zidovudine and 
didanosine). HAART (including PIs and NRTIs) is associated with the lipodystrophy 
syndrome, with insulin resistance as an important feature. Furthermore, total adiponectin 
(TA), an insulin sensitizing hormone is also decreased in these patients. Recently, the 
high molecular weight (HMW) form of adiponectin has been shown to be the active form 
and the HMW:TA ratio is known to be a better marker of insulin resistance than either 
form individually.  
Objectives: To establish whether HMW:TA ratios are lower in HIV patients receiving 
PIs, compared with those not on PIs and to establish whether the HMW:TA correlates 
with other markers of insulin resistance in these patients.  
Methodology: 66 HIV-infected African females were recruited: 22 on regimen 2 (PI 
group) for at least 6 months, 22 on regimen 1 (non-PI group) for the same period and 22 
treatment naïve (TN). All the groups were matched for BMI and age. Patients with overt 
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were measured. Adiponectin levels (TA and HMW) were analysed on fasted serum 
samples using the Alpco DiagnosticsTM Adiponectin (Multimeric) enzyme immunoassay. 
Glucose (fasting and 2h post 75g oral glucose) and fasting insulin were measured and 
mathematical models of insulin resistance (HOMA-IR, HOMA-β% and QUICKI) 
 calculated. Data were analysed non-parametrically.  
Results: The PI and non-PI groups had significantly lower HMW adiponectin levels than 
the TN group (median 2.23 and 3.49, respectively, vs 5.29mg/l; p<0.005), but did not 
differ significantly from each other. Similarly, TA was significantly lower in both 
treatment groups compared with the TN group (median 5.64 and 7.3, respectively, vs 
9.03mg/L; p<0.05), but did not differ significantly between the PI and non-PI groups. In 
contrast, the HMW:TA ratio was significantly lower in the PI group than in both the NPI 
(p<0.05) and TN (p<0.0001) groups, and was also lower in the non-PI  than in the TN 
group (p<0.05). Insulin, glucose, HOMA-IR, HOMA-β% and QUICKI did not differ 
significantly amongst the groups. The HMW:TA ratio correlated negatively with WHR 
(p<0.005) and fasting insulin (p<0.005). A negative, though not statistically significant, 
correlation was also found between HMW:TA ratio and fasting and 2h glucose levels, as  
well as age and BMI. 
Conclusion: These data demonstrate that both PI- and non-PI containing HAART 
regimens significantly lower the HMW:TA ratio in HIV patients, with the ratio more 
significantly decreased in the PI-containing regimen, implying that PIs and NRTIs have 
an additive effect on the HMW:TA ratio. Although the HMW:TA ratio correlated 
negatively with indirect markers of insulin resistance, no overt insulin resistance was 
demonstrated.  HMW:TA ratio may therefore be a more sensitive marker of insulin 
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D.7. CLINICAL CHEMISTRY GUIDELINES FOR SUBMISSION OF 
MANUSCRIPT  
This is an abridged version of the guidelines. The full version may be found at the 
following web address:  
http://www.clinchem.org/info_ar/info_authors.shtml 
 





Information for Authors 
 




Clinical Chemistry, issued monthly, is published in print and electronically by the 
American Association for Clinical Chemistry. The journal welcomes contributions, either 
experimental or theoretical, in the field of laboratory medicine. It is the leading forum for 
peer-reviewed, original research on innovative practices in today’s clinical laboratory. In 
addition to being the most cited journal in the field, Clinical Chemistry has the highest 
Impact Factor among journals of clinical chemistry, clinical (or anatomic) pathology, 
analytical chemistry, and the subspecialties, such as transfusion medicine and clinical 
microbiology.  
Submissions of the following nature are welcomed:  
• Basic materials or principles  
• Analytical techniques  
• Molecular diagnostics  
• Test utilization or testing-related health or financial outcomes  
• Instrumentation  
• Data processing  
• Statistical analyses of data  
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• Laboratory animal studies of chemically-oriented problems of human disease  
Contributions should consist of subject matter that is original and significantly advances 
the state of knowledge of clinical chemistry, and conclusions that are justified from the 
design of the experiments and the data presented. The information must be sufficiently 
detailed to permit replication of the work by a competent worker in the field. Lastly, the 
writing must be clear, concise and grammatically correct. 
 
Equal consideration is given to original manuscripts in English from any country, 
regardless of membership in the Association. It is, however, advised that all non-English 
speaking authors enlist the aid of a native-English speaking colleague to correct English 
language usage before submission. Submissions must adhere to the “Uniform 
Requirements for Manuscripts Submitted to Biomedical Journals” (1).  
Submissions are accepted via the manuscript tracking system at 
http://submit.clinchem.org. The “Information for Authors” will offer assistance with 
journal style and requirements. Please contact the Editorial Office via e-mail should you 
have any questions or need assistance: clinchemed@clinchem.aacc.org  
References:  
1. International Committee of Medical Journal Editors. Uniform requirements for 
manuscripts submitted to biomedical journals. Ann Intern Med 1997;126:36-47. 
[Full Text]  
 
Standards for Reporting Scientific Data 
• Statistics  
• Studies with Human Subjects  
Statistics 
Describe statistical methods with enough detail to enable a knowledgeable reader with 
access to the original data to verify the reported results.  
When possible, quantify findings and present them with appropriate indicators of 
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Avoid sole reliance on statistical hypothesis testing, such as the use of P values, which 
fails to convey important quantitative information.  
When appropriate, confidence intervals should be presented.  
 
Studies with Human Subjects  
 
Authors are responsible for ensuring compliance of human studies with the Helsinki 
Declaration of 1975 as revised in 1996: 
http://www.wma.net/e/humanrights/policy_meetings.htm. Approval by the appropriate 
institutional committee on human research (Institutional Review Board) must be 
documented in the manuscript and, unless excepted by that committee, informed consent 




Research or scientific articles are submitted directly from authors. There are no 
restrictions on topics that are considered for publication, as long as the subject matter is 
original and relates experimentally or theoretically to the field of laboratory medicine. 
The information must be sufficiently detailed so that readers not only can understand and 
appreciate the material presented, but also permit replication of the work by other 
scientists in the field.  
 
Articles should consist of a structured abstract limited to 250 words while the main text 
should not exceed 3,500 words. The manuscript should have no more than 40 references 
and a total of 6 tables and/or figures. Supplemental data are permitted for Articles.  
 
Manuscript Preparation  
• Author Contribution Requirements  
• General Guidelines  
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• Title Page  
• Abstract  
• Text  
• Disclosures/Conflict of Interest  
• Acknowledgements  
• References  
• Tables  
• Figure Captions  
• Figures  
• Color  
• Supplemental Data  
 
Author Contribution Requirements  
 
Manuscripts are considered for publication with the understanding of the following:  
1. Each author has participated significantly in the work in a substantive way and is 
prepared to take public responsibility for its content;  
2. Each listed author must have  
3. participated in conception, design, analysis, or interpretation;  
4. drafted or critically revised the manuscript; and  
5. read and approved the final submitted manuscript and revisions.  
Any change in authors and/or contributors after initial submission must be approved by 
all authors. This applies to additions, deletions, change of order to the authors, or 
contributions being attributed differently.  
Any alterations made to the manuscript after submission must be approved by the editor. 
Authors may upload the request letter to the online submission system as a supplemental 
file or send the letter via e-mail to the Clinical Chemistry editorial office; 
clinchemed@clinchem.aacc.org . The editor may contact any of the authors and/or 
contributors to ascertain whether they have agreed to any alteration.  
1. The International Committee of Medical Journal Editors (ICMJE) Uniform 
Guidelines for Manuscripts Submitted to Biomedical Journals (1) specifically 
state that “all contributors who do not meet the criteria for authorship, such as a 
person who . . . provided purely writing assistance" be named in the 
acknowledgments. 
 
2. Important contributions to an article should be recognized and appropriately 
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Good medical writers and editors can make valuable contributions to the 
publication process, often improving the clarity of the communication, 
broadening the scope of literature review, providing an extra level of data review, 
adding balance and objectivity, and shortening the time needed for manuscript 
development.  
 
The American Medical Writers Association (AMWA) http://www.amwa.org 
believes that these important contributions deserve recognition. 
 
3. Readers benefit from knowing about the involvement of professional writers and 
editors.  
 
Disclosing the editorial contribution and the source of funding of the writer and 
editor allows the reader to make informed judgments about the objectivity of the 
article.  
 
Note that the AMWA position statement recommends acknowledgment of 
pertinent professional or financial relationships as well as acknowledgment of the 
contributions of writers and editors.  
 
It also recommends that the person being acknowledged be given the opportunity 
to grant or refuse permission for the acknowledgment.  
References:  
1. International Committee of Medical Journal Editors. Uniform requirements for 
manuscripts submitted to biomedical journals. Ann Intern Med 1997;126:36-47. 
[Full Text]  
 
Manuscript Guidelines  
• MS Word document (.doc) is required for all submissions.  
• All figures must be uploaded separately as Image Files in Tagged Image File 
Format (.tiff), Encapsulated Postscript (.eps) or PowerPoint (.ppt) with embedded 
fonts.  
• All submissions must be double-spaced, 1 inch margin, twelve-point font size in 
Arial, Helvetica, Times New Roman and Symbol font (for non-text characters).  
• All submissions must be page numbered.  
• Do not use headers or footers.  
• Use standard abbreviations and define all nonstandard abbreviations.  
• All submissions require a title page.  
• SI units must be used throughout your submission. Conventional units may only 
be added as additional information in parentheses after the SI units. SI units are 
available at Bureau International des Poids et Mesures.  
• Supplemental Data are accepted for online publication only and is limited by 
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• Follow the guidelines for length restrictions, abstract, reference, table and figure, 




















Article 3,500 S: 250 40 6 Yes 
Bookshelf 500 Non Applicable 5 1 No 
Brief 
Communication 
1,500 S: 250 20 1 each*** Yes 




w/ 3-5 questions 




Non Applicable 10 2 No 
Commentary 300 Non Applicable 
Non 
Applicable 
Non Applicable No 
Editorial 1,500 Non Applicable 15 Non Applicable No 
Letter to the Editor 
/ Reply 
750 Non Applicable 5 1*** No 
Mini-Review 3,500 S: 250 40 4 Yes 




Opinion 1,500 Non Applicable 15 1 No 
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Point/Counterpoint 1,500 Non Applicable 15 1 No 
Reflection 2,000 Non Applicable 20 1 No 
Review 5,000 S: 250 75 6 Yes 
Special Report 5,000 S or U: 250 40 4 Yes 
*Word limit consists of the body of the manuscript only; it does not encompass the title page, abstract, 
acknowledgments, references, tables, figure legends, figures, or Clinical Case descriptions, questions, and 
points to remember. 
 
**Structured abstracts contain the headings (1)BACKGROUND, (2)METHODS, (3)RESULTS, 
(4)CONCLUSIONS for all applicable article types except for Reviews and Mini-Reviews. Abstracts for 
Reviews and Mini-Reviews contain the headings (1)BACKGROUND, (2)CONTENT, (3)SUMMARY. 
 





Journal Categories  
 
Articles are grouped in the journal according to subject. Upon submission, authors are 
required to select the journal category that best describes their manuscript from the list 
indicated below:  
• Molecular Diagnostics and Genetics (MDG)  
• Evidence-Based Laboratory Medicine and Test Utilization (TUO)  
• Hemostasis and Thrombosis (HAT)  
• Proteomics and Protein Markers (PPM)  
• Cancer Diagnostics  
• Lipids, Lipoproteins, and Cardiovascular Risk Factors (LLP)  
• Drug Monitoring and Toxicology (DMT)  
• Hematology (HEM)  
• Endocrinology and Metabolism (END)  
• Point-of-Care Testing  
• Automation and Analytical Techniques (AAT)  
• Informatics and Statistics  
• Laboratory Management (LMA)  
• General Clinical Chemistry (GCC)  
• Animal Clinical Chemistry (ANI)  
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• Pediatric Clinical Chemistry (PED)  
• Nutrition (NUT)  
• Infectious Disease  
• Other Areas of Clinical Chemistry (OTH)  
 
Title page  
 
The first page of the manuscript should include the following information: (1) full title of 
submission, which should include only generic, not trade, names when describing a test, 
assay, etc.; (2) running head of fewer than 65 characters (including spaces); (3) list of all 
authors (first name, middle initial, last name in that order); (4) names of each author’s 
institution and an indication of each author’s affiliation; (5) name, address, telephone and 
fax number, and e-mail address of the corresponding author; (6) keywords; (7) list any 
previous presentation of the manuscript; (8) list abbreviations, in order cited; (9) list any 
“Human Genes" discussed in the paper. For each gene, indicate the gene symbol and 
gene name approved by the HUGO Gene Nomenclature Committee. Include other 
name(s) that are used in the paper or are widely used in the literature for the gene.  
Abstract (Structured and Unstructured)  
 
Structured abstracts should be formatted to include separate headings of: (1) 
BACKGROUND, (2) METHODS, (3) RESULTS, and (4) CONCLUSION. For Mini-
Review and Review articles the headings should be: (1)BACKGROUND, (2) 
CONTENT, and (3) SUMMARY.  
Unstructured abstracts do not require separate headings.  
Text  
 
The body of the manuscript should be written as concisely as possible and must not 
exceed the manuscript category word limits described herein. All pages must be double-
spaced and all lines numbered. The body of the paper should include: Introduction, 
Materials and Methods, Results and Discussion.  
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• Materials and Methods - how was the study done?  
• Results - what did the study find?  
• Discussion - what might it mean, why does it matter, what next?  
Full corporate names of manufacturers of materials should be utilized and should include 
the city, state, and e-mail or website of the company.  
 
SI units are required; however, conventional units may follow in parenthesis.  
 
Use of human subjects requires a statement in the text indicating whether the procedures 
followed were approved by your institution's responsible committee or were in 
accordance with the current revision of the Helsinki Declaration and whether subjects 
gave informed consent.  
Disclosures/Conflict of Interest  
 
All authors are required to complete a full disclosure form upon submission. The 
disclosure form is electronic and completed during the submission process within the 
Bench>Press submission system. Complete disclosures must be submitted electronically, 
and should not be included within the submitted manuscript. Failure to adhere to this rule 
may result in a return of the submission to the author for correction. 
 
In order to complete disclosures, registration with Clinical Chemistry is required for all 
authors. 
 
The American Medical Writers Association (AMWA) recognizes the valuable 
contributions of biomedical communicators to the publication team. Biomedical 
communicators who contribute substantially to the writing or editing of a manuscript 
should be acknowledged with their permission and with disclosure of any pertinent 
professional or financial relationships. In all aspects of the publication process, 
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manuscript directly above the reference section in a separate paragraph heading labeled 
“Acknowledgments.” They should not appear as footnotes.  
References  
 
References should appear in a separate section directly following the body of the 
manuscript. The section must be labeled “References” with no additional punctuation.  
• Italics or boldface type is prohibited in the referenced citations.  
• List and number the references in the order that they appear in the text.  
• Do not use the MS Word document (.doc) numbering tool. Number each 
reference manually with the numeral, a period, followed by a space.  
• For articles with more than seven authors, list the first six authors followed by "et 
al." For seven or fewer, list all authors.  
• Authors’ names are inverted (last name, first/second initial). Do not add periods 
or commas within an individual author name; however, separate author names 
with a comma and end the author list with a period (Smith J, Doe JJ, Adams B.).  
• Capitalize only the first word of the title or subtitle, and any proper names that are 
part of the title. The title should end with a period.  
• The Journal names should be abbreviated as indicated at PubMed. For a list of 
journal abbreviations, please visit: LinkOut Journals.  
• Do not add a period after the journal abbreviation, but continue with a space 
followed by the year.  
• The year should be followed by a semicolon and then the volume number which 
is followed by a colon and then the page numbers; delete redundant numbers, for 
example 1998;12:231-45.  
• Do not include the months in parentheses, this information is not needed.  
• Use inclusive page numbers for articles and book chapters.  
Abstract and supplement numbers should be provided, if applicable. Citations of 
unpublished abstract books, manuscripts in preparation or under review, personal 
communications, and manufacturers’ information should only be cited in the text and 
should not appear in the reference list. Personal communications should also be listed 
parenthetically and should contain the first initial and last name of the contact as well as 
the month and year of the communication. Published manuscripts and manuscripts that 
have been accepted and are pending publication should be cited in the reference list.  
 
In press references cited in the reference list must be accompanied by a copy of the cited 
manuscript and a letter of acceptance, or a complete author proof from the publisher. 
These resources should be uploaded as supplemental data along with the manuscript and 
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The submission system will extract the references from the submitted MS Word 
document (.doc) to display in a hyperlinked HTML format as an aid for reviewers and 
editors. This linking option allows for the checking of the correct formatting and the 
accuracy of the citations.  
 
Authors must check the linking of their references to PubMed during the “Ready for You 
to Proof” stage of submission. Correct linking of the references depends on strict 
adherence to Journal style as indicated.  
Reference Style  
• Journal article with seven or fewer authors:  
1. Vermeersch P, Mariën G, Bossuyt X. A case of pseudoparaproteinemia on 
capillary zone electrophoresis caused by geloplasma. Clin Chem 2006;52:2309-
11.  
• Journal article with more than seven authors:  
2. Fiechtner M, Ramp J, England B, Knudson MA, Little RR, England JD, et al. 
Affinity binding assay of glycohemoglobin by two-dimensional centrifugation 
referenced to hemoglobin Alc. Clin Chem 1992;38:2372–9.  
• Abstract:  
3. Hortin GL, King C, Kopp J. Quantification of rhesus monkey albumin with 
assays for human microalbumin [Abstract]. Clin Chem 2000;46:A140-1.  
• Editorial:  
4. Demers LM. New biochemical marker for bone disease: is it a breakthrough? 
[Editorial]. Clin Chem 1992;38:2169–70.  
• Letter to the Editor:  
5. Davey L, Naidoo L. Urinary screen for acetaminophen (paracetamol) in the 
presence of N-acetylcysteine [Letter]. Clin Chem 1993;39:2348–9.  
• Book Chapter:  
6. Rifai N, Warnick GR. Lipids, lipoproteins, apolipoproteins, and other 
cardiovascular risk factors. In: Burtis CA, Ashwood ER, Bruns DE, eds. Tietz 
textbook of clinical chemistry and molecular diagnostics. 4th Ed. St. Louis: 
Elsevier Saunders 2006:903-81.  
• Thesis:  
7. Haughton MA. Immunonephelometric measurement of vitamin D binding 
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• Books and Monographs (serial volumes should be treated as journals):  
8. Harrell FE Jr. Regression modeling strategies. New York: Springer; 2001. 
9. Bailar JC III, Mosteller F, eds. Medical uses of statistics, 2nd Ed. Boston: 
NEJM Books; 1992:449pp.  
• Publish-Ahead of Print:  
10. Milbury CA, Li J, Makrigiorgos GM. PCR-based methods for the enrichment 
of minority alleles and mutations. [Epub ahead of print] Clin Chem February 6, 
2009 as doi:10.1373/clinchem.2008.113035.  
• Supplement:  
11. Castelli WP. Lipids, risk factors and ischaemic heart disease. Atherosclerosis 
1996;124 Suppl:S1-9.  
• Internet Source:  
12. American Association for Clinical Chemistry. AACC continuing education. 




Tables are considered text. They should appear embedded as part of the submission 
directly following the reference section. Each table should appear on an individual page. 
Manuscripts will be returned to authors if the tables are uploaded as separate files.  
Each table should be clearly labeled and numbered consecutively with Arabic numerals 
(Table 1, Table 2, etc.). The abbreviations used must be defined. As with the text, SI 
units must be used; however, conventional units may be added in parentheses. 
Conversion factors may be added as footnotes. Indicate explanatory footnotes with 
superscript lowercase italic letters in alphabetical order.  
Tables should not include parts. Tables with parts (Table 1A, Table 1B, etc.) will be 
returned to authors for correction.  
Table captions should be limited to 60 words.  
Each column of an individual table must have a heading and be clearly defined. Indicate 
explanatory footnotes with superscript lowercase italic letters in alphabetical order.  
Color tables will be considered for publication. As in the case with color figures, the 
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first color table and $500 for each subsequent color table, or part thereof. Please note the 
author agreement to pay in the cover letter.  
Large, complex, or tables that include graphic elements should be submitted as figures or 
as supplemental data for online publication only. The Editor may choose to make any 
table supplemental as he/she deems necessary.  
Figure Captions  
 
Figure captions and sub-captions must be listed together on an individual page directly 
following the tables or the references if submission does not include tables. Each figure 
requires a figure caption and should be clearly labeled (Figure 1, Figure 2, etc.). Multi-
panel figures; figures with parts (a, b, c, etc.), should be distinctively labeled (Figure 1A, 
Figure 1B, Figure 2A, etc.).  
Figure captions should be limited to 60 words.  
If a figure has been published previously, acknowledge the original source in the figure 
caption and submit written permission from the copyright holder to reproduce the figure 
as supplemental data.  
Figures  
 
All figures must be uploaded separately as image files in Tagged Image File Format 
(.TIFF) or Encapsulated Postscript (.EPS). Microsoft Power Point (.PPT) is also 
acceptable; however, the graphics must contain embedded fonts with one image per slide, 
one slide per file. Each image should have a resolution of 600 dots-per-inch (dpi). More 
detailed specifications can be found on our print publication vendor’s page at CADMUS 
Digital Art Support.  
The submission system is designed to retrieve the manuscript file and separate image 
file(s) and combine or merge the files into an individual Portable Document Format 
(.PDF) for reviewing purposes. It is the responsibility of the author to verify the quality 
of the image file(s) remains after the conversion to PDF. It may be necessary to alter the 
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Submissions will be returned to authors if the figures are embedded within the 
manuscript file and not uploaded separately, or the figures have become eligible in the 
merged PDF.  
Do not place unnecessary graphics, such as borders, in or around your figure. Pay 
particular attention to the quality of the lines, symbols, and patterns. Published figures are 
reduced to 1 column (85mm) or 2 columns (176 mm) in width. If, at that width, the figure 
symbols or lettering are not clear, you will need to increase the font size. Letters should 
be 8/10 points when reduced, subscripts no less than 6 point. Initial capitals and lower 
case letters and a medium (not bold) sans serif font is required. European PI, Helvetica, 
Mathematical PI, Times Roman, and Symbol fonts are Type 1 PostScript fonts supported 
by our printer for the creation of digital art figures.  
If publication quality electronic figure files cannot be provided, acceptable publication 
prints are:  
• Halftone: glossy prints  
• Line drawing: glossy prints, laser prints on coated (nonabsorbent) laser-printer 
paper, or drawings in black India ink on tracing paper.  
• Color: glossy prints, laser prints on coated (nonabsorbent) laser-printer paper  
[Halftone: Image with blocks or portions that are gray opaque, such as a photograph; Line drawing: Image 
is in black and white only, such as a line graph; Color: Images where color is necessary to the meaning of 
the image]  
The x-axis and y-axis should be clearly labeled, and the units of measurements given. 
This includes using decimal points instead of commas, italicizing species or gene 
symbols, and using U.S. English.  
Color  
 
The costs of publishing color illustrations in print will be borne by the author. As with 
tables, costs are $1500 for the first figure and $500 for each subsequent figure, or parts of 
figures. Upon acceptance, authors will be billed for the color costs unless a request to 
print figures in black and white is received via cover letter or e-mail. Color versions of 
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note your color preference and/or your agreement to pay for color printing in your cover 
letter.  
Supplemental Data  
 
Figures or tables too large for print, manuscript material that exceeds the limitation for 
the specific submission type, or appendices should be submitted for online publication 
only. These files should be marked and uploaded separately as supplemental files during 
submission, and should be referenced within the text as supplemental data (i.e., "See 
Supplemental Data Table 1", "See Supplemental Data Figure 1", etc.). Supplemental files 
must be labeled consecutively (i.e., Supplemental Data Table 1, Supplemental Data Table 
2, Supplemental Data Figure 1, Supplemental Data Figure 2, etc.).  
Captions for the supplemental data should be uploaded as a separate supplemental file or 
embedded within the supplemental data/table/figure file. Do not include the supplemental 
captions in your manuscript file.  
Please be advised, supplemental data are permitted for Article, Brief Communication, 
Inspiring Minds, Mini-Review, Review, and Special Report submissions only. 
Manuscripts of all other types with supplemental data will be returned to authors.  
Supplemental data will be reviewed as part of the manuscript and will be evaluated for its 
importance and relevance; however, it should not appear in the “Peer-reviewed PDF” file 
created by the submission system.  
If accepted and posted online, the supplemental data will be referenced in the text of the 
print article directing readers to the URL of the Web site.  
 
Authors are expected to identify to the Editor any other manuscripts (in print, accepted, 
have been submitted, in preparation) that relates to the submitted manuscript, especially 
if any patients or results are described in both.  
Questions related to the possibility of perceived redundant publication or fragmentation 













 Page 123 of 135 
FIERDOZ OMAR OMRFIE001 MMED (CHEM PATH)  
 
Clinical Chemistry Editorial Office  
 
Clinical Chemistry 
1850 K Street, NW 
Suite 625 




(202) 420-7678  
(202) 833-4576 [FAX]  
 
Sheehan Misko, Managing Editor: smisko@aacc.org 
Sarah J. Walker, Editorial Coordinator: swalker@aacc.org 
Rachelle Detweiler, Editorial Coordinator: rdetweiler@aacc.org 
Robert Sumner, Editorial Coordinator: bsumner@aacc.org 
 
Please include the corresponding author’s e-mail address and the manuscript number on 
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D.8. UNIVERSITY OF CAPE TOWN DISSERTATION GUIDELINES 
Minimum Requirements for Dissertations for MMed and MPhil for Subspecialities 
Degrees 
Following extensive discussion with Heads of Divisions, Dr S Kalula and Prof S Kidson 
recommend the following minimum criteria for dissertations for MMed and MPhil 
(subspeciality) degrees: 
 
The MMed minor dissertation (or the MPhil dissertation in the case of sub-specialities) is 
one of three examination components of the MMed/MPhil degree. This minor 
dissertation carries one third of the weight of a full master’s dissertation in terms of its 
credit weighting. 
The dissertation must be a study containing the results of an analytical, quantitative, or 
epidemiological study carried out by the candidate (for certain disciplines, the candidate 
may chose instead to do a qualitative study, an audit cycle or a formal systemic review). 
A case report is not acceptable for the dissertation. 
The dissertation must be the result of independent work of the candidate conducted under 
the guidance and direction of a supervisor(s) and should demonstrate evidence of an 
ability to undertake research, to adequately interpret results and to comprehensively and 
critically review the relevant literature. Although the findings of the research need not 
necessarily be original, they must be seen to advance scientific understanding. The topic 
and scope of research will depend on the particular disciplines and must be agreed upon 
in consultation with the supervisor(s). 
Research protocol 
Candidates intending to register for the MMed/MPhil Part III are required to submit a full 
research protocol for approval to their respective Departmental Research Committee 
(DRC). The candidate must also obtain FHS UCT Ethics approval prior to conducting 
their research. This full research protocol (together with a copy of the ethics approval 
letter) must be submitted to the postgraduate administration for approval by the Board of 
the Faculty of Health Sciences, prior to commencement of the research. For most 
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The research protocol should outline the scope and content of the dissertation and must 
include the title of the proposed dissertation, name of the supervisor(s) and their brief 
curriculum vitae. 
Submission of dissertations 
On completion, the dissertation should be submitted to the Faculty Postgraduate Officer. 
The candidate should inform the Faculty Officer one month in advance of the intention to 
submit. 
Submission deadlines: 
1. March 15th for June graduation 
2. August 15th for December graduation 
Supervisors will be requested by the Faculty Postgraduate Officer to submit a letter 
supporting submission. This letter should be supplied by the primary supervisor. If this 
supervisor is external, the internal supervisor must be kept informed at every stage of the 
process. Specific submission requirements may be set by individual disciplines.2 
Note on fees: To avoid attracting fees, dissertations need to be submitted before the 
beginning of the first quarter (first day of academic year), and before the start of the 
second semester (mid July) to qualify for a 50% fee rebate. 
Supervisors 
One cannot overemphasize the importance of identifying a dissertation supervisor as 
early as possible.  The supervisor should be an individual who can relate to the 
candidate’s research project, be available for frequent and regular discussion and advice, 
and someone with whom the candidate can develop a good working relationship. Where 
specialised equipment and/or laboratory work is required for the study, the supervisor 
should assist in facilitating such access to such facilities. Supervisors may assist 
candidates in developing scientific communication skills but they are not required to do 
detailed editing or correction of spelling, grammar, or style. They may refer candidates to 
the UCT Writing Centre for this purpose. 
The primary supervisor may be based outside the candidate’s home department, faculty 
or university. In such a case, an internal (or secondary) supervisor will be required in 
addition to the primary supervisor, to serve as a guide and link to discipline-specific 
procedures. Primary supervisors retain responsibilities to the candidate and the university 
until the dissertation process is complete. 
Please note: in order to assist a candidate with a master’s research topic the supervisor 
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primary supervisor does not hold a higher degree or equivalent (such as a Fellowship of 
The College of Medicine of South Africa), then a secondary supervisor who has a higher 
degree will need to be appointed in addition to the primary supervisor. 
Candidates are strongly encouraged to publish the study with the supervisor(s) as co-
author(s). This may require work beyond the graduation date. Such arrangements should 
be discussed and documented in advance. 
2 For Public Health Medicine and Occupational Medicine the dissertation must be 
submitted for examination at least 4 months prior to the deadline for registration for the 
examinations of the relevant College. This is in order to ensure that a final examination 
mark for the dissertation can be submitted by the candidate to the College of Medicine of 
South Africa (CMSA) at the time of registration as required by CMSA examination 
regulations.  
The dissertation 
Submission of the dissertation should satisfy the following criteria: 
 
1. The title page should contain the candidate’s name, dissertation title and the name of 
the university. 
It must also state the degree, e.g. Master of Medicine (MMed) in Public Health Medicine, 
Occupational Medicine, Family Medicine, Surgery, etc. The title page should also 
include a statement to the effect that the research report is based on independent work 
performed by the candidate and that neither the whole work nor any part of it has been, is 
being, or is to be submitted for another degree to any other university. It must also state 
that this work has not been published prior to registration for the abovementioned 
degree. 
 
2. The body of the dissertation, which must be structured in 4 parts, should include the 
following:  
Part A: The protocol (as approved by the Departmental Research Committee and Faculty 
Research Ethics Committee). The protocol should not exceed 4000 words. 
Part B: A structured literature review appropriate to the subject matter and methods of 
the dissertation. The literature review must, amongst other things, show that the student is 
sufficiently acquainted with the relevant literature and is able to perform a critical 
appraisal and, if appropriate for the topic, show a good understanding of evidence-based 
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A suggested structure for the literature review is as follows: 
a) Objectives of literature review 
b) Literature search strategy, including inclusion and exclusion criteria 
c) Quality criteria - some leeway will be allowed here, as candidates will vary in their 
ability to appraise studies. This will also vary with the nature of the dissertation. 
d) Summary or interpretation of literature 
e) Identification of gaps or needs for further research 
f) References (which will overlap with but will not be the same lists as in the journal 
article and protocol) 
Part C: The results of the study must be presented in the form of a manuscript of an 
article for a named peer reviewed journal, meeting all the requirements set out in the 
“Instructions for Authors” of that journal, including the word count and referencing style. 
(Unless specially motivated, the journal chosen will need to allow for at least 3000 words 
excluding abstract, tables, figures and references). The “Instructions to Authors” of the 
journal must be appended. The journal chosen for publication must be appropriate to the 
subject matter of the dissertation and accredited by the Department of Education or listed 
in the citation index of the Institute for Scientific Information (ISI). 
Important note: the candidate need not have submitted the article, not is the acceptance of 
the article and requirement for passing the degree. The norm of practise is to publish the 
study with the supervisor(s) as co-author(s) and candidates are strongly encouraged to 
submit their manuscript either before or after examination of the mini-dissertation. 
Part D: All supporting documents including: 
• Questionnaire/data capture instrument 
• Consent forms and any related participant information sheets 
• Technical appendices, including, if considered necessary, any additional tables not 
included in the main manuscript for the examiner to have available. These should be 
accompanied by a brief narrative. 
• Official Ethics approval letter from the Faculty Research Ethics Committee 
 
3. The article does not have to be submitted to the journal in order to meet academic 
requirements. 
 
4. A candidate must submit 2 copies of the dissertation in temporary binding, and an 
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Examiners 
The full dissertation will be submitted for examination through the Postgraduate office of 
our Faculty to two external examiners (nominated by the supervisors and HOD).Three 
examiners will be nominated, two of which are invited to examine, and one held as an 
alternate. All examiners must be external to UCT. These nominations are circulated to 
the Faculty Dissertation Committee. It is the supervisor’s (or 
co-supervisor’s) responsibility to submit names of potential examiners to the Faculty 
Officer when the candidate is ready to submit. 
The examiners will be well briefed regarding the specific requirements and criteria for 
submission and examination of the mini-dissertation. Such criteria will clearly explain 
the difference between the minidissertation and a Master’s degree by dissertation alone. 
Details required for each examiner are: academic qualifications, postal and/or physical 
address, telephone and fax numbers and e-mail address, and one paragraph description of 
their standing in the relevant field (drawn from their CV if need be.) 
The candidate may not be informed of the identity of the examiners. After the outcome of 
the minidissertation has been finalised, the examiners’ identities are made known if the 
examiners have indicated that they do not object to this. 
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